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Conjugated linoleic acid (CLA) and the long chain ω-3 polyunsaturated fatty acids (LC
ω-3 PUFAs) represent unique examples of bioactive nutrients that show a wide range of
functions in biological systems. De novo lipogenesis (DNL) is a critical metabolic process
that is implicated in wide range of physiological and pathological processes. The objective
of this dissertation was to investigate the molecular mechanisms of different bioactive fatty
acids (FAs) on some aspects of lipid metabolism. The initial investigation was to examine
the role of thyroid hormone responsive spot 14 (S14) in the regulation of lipid synthesis in
adipose tissue of growing mice and the possible role of S14 in the CLA-induced reduction in
fat accretion. Wild type (Wt) and S14 null mice were supplemented with CLA for 14 days.
Knocking out the S14 gene significantly reduced the epidydemal fat depot, but there was no
corresponding reduction in the mRNA abundance for lipogenic genes. CLA treatment sig-
nificantly reduced the total dissected fat tissue and downregulated the mRNA abundance of
SREBF-1c, ACACA and FASN regardless of the genotype. This suggests that the S14 protein
is not involved in the transcriptional regulation of lipogenic enzymes and expression of the
S14 gene is not essential for the CLA delipidative mechanism. A second focus of this thesis
was to examine the effects of LC ω-3 PUFAs on lipid synthesis in lactating mice. Mice were
given a diet containing 10% fish oil (FO) from d 6 to 13 of lactation. Results showed no differ-
ences among treatments in the proportion of de novo synthesized milk FAs or the lipogenic
capacity of mammary explants. In addition, mRNA abundance of key enzymes in the FA
synthesis pathway were not different among treatments. In contrast, FO treatment resulted
in an impressive decrease in hepatic lipid accumulation and downregulation of lipogenic
gene expression. Overall, these results demonstrate that dietary FO supplementation to lac-
tating mice had no effect on mammary lipogenic variables, but effects on hepatic lipogenesis
were obvious. The final investigation was to investigate the mechanism of CLA induced
milk fat depression (MFD) in lactating ewes and to determine their suitability to serve as
convenient model for investigations of mammary lipid metabolism in lactating cows. Lac-
tating dairy ewes received a CLA supplement containing trans-10, cis-12 CLA for 10 wks.
CLA supplementation resulted in a decrease in milk fat secretion with de novo synthesized
FAs being most markedly affected. Consistent with this, a coordinated downregulation in
the mRNA expression of key enzymes involved in DNL occurred. Thus, lactating ewes are
responding to the trans-10, cis-12 CLA in a manner similar to cows and should represent a
good model to continue mechanistic studies of the regulation of lipid metabolism in mam-
mary gland.
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Chapter 1
Introduction
In affluent societies the science of nutrition is at a new frontier. It is progressing from the con-
cept of ‘adequate nutrition’ for survival to that of ‘optimal nutrition’ for improving health
and prevention of chronic diseases [1]. Until recently, nutrition research concentrated on
nutrient deficiencies and impairment of health. However, due to a growing realization that
the effects of nutrition on health and disease cannot be understood without a profound un-
derstanding of how nutrients act at the molecular level, nutrition research has undergone
an important shift in focus from epidemiology and physiology to molecular biology and
genetics. The advent of genomics has created unprecedented opportunities for increasing
our understanding of how nutrients modulate gene and protein expression and ultimately
influence cellular and organismal metabolism.
From a nutrigenomics perspective, nutrients are considered to be signaling molecules
that, through appropriate cellular sensing mechanisms, result in translation of these dietary
signals into changes in gene, protein, and metabolite expression [2]. The information that
allows nutrients to activate specific signaling pathways is contained within their molecular
structure and minor changes in structure, for example, saturated vs unsaturated fatty acids
(FAs) or the position and geometry of the double bonds in a FA can have a profound influ-
ence on which sensor pathways are activated. Nutrients can be regarded as functional if they
have been proved to affect one or more target functions in the body, beyond the traditional
2nutritional effects, in a way that is relevant to an improved state of health and well-being
and a reduction in the risk of chronic diseases [3].
Fat has traditionally been regarded to be important as a calorie-dense nutrient and as a
source for essential FAs. In recent years, specific FAs have been increasingly recognized as
important biological regulators. In this regard, CLA and the LCω-3 PUFAs, eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) have attracted considerable attention because
of their reported anticarcinogenic, antiatherogenic, antiobesity, antiadipogenic, and antiin-
flammatory biological activities [4, 5]. All of these potentially positive target functions high-
light the importance of these bioactive polyunsaturated fatty acids (PUFA) at a time when
the increasing prevalence of obesity and the metabolic syndrome affects not only adults but
also a worrisome proportion of adolescents and children. CLA refers to all the positional and
geometric isomers of linoleic acid. CLA isomers are formed when reactions shift the location
of one or both of the double bonds of linoleic acid in such a manner that the two double
bonds are no longer separated by an interceding carbon. On the other hand, FA that have a
longer chain length, higher number of double bonds, and an n-3 double bond arrangement
represent LC ω-3 PUFAs with distinct and unique biological properties that separate them
and their metabolic products from other FAs. Many of the effects of these bioactive PUFAs
in both cell biology and human health and disease relate to their ability to regulate gene
expression and subsequent downstream events.
The DNL from simple substrates, glucose and acetate in monogastrics and ruminant an-
imals respectively, requires collaboration and harmony of multiple metabolic pathways, in-
cluding glycolysis and pyruvate oxidation or activation of acetate to generate acetyl-CoA for
FA synthesis, NADPH generation to supply the reductive power, packaging of FAs into a
glycerophosphate backbone, and finally, packaging to export triglycerides in liver (lipopro-
teins) or mammary tissue (milk fat globules). This diverse array of metabolic pathways and
their key enzymes are highly active in the liver, adipose and lactating mammary gland and
interestingly in many human tumors.
3In addition to genetic, hormonal and transcriptional control, DNL is nutritionally regu-
lated and highly responsive to dietary FA composition. For example, dietary supplementa-
tion of the trans-10, cis-12 CLA was able to induce milk fat depression (MFD) in ruminant
and non-ruminant animal models [6]. Moreover, the dietary LC ω-3 PUFAs has been shown
to downregulate hepatic glycolysis and de novo lipid synthesis pathways [7].
The proposed mechanisms by which bioactive FAs effect lipid metabolism involves reg-
ulation of the abundance and activity of metabolic nuclear receptors and lipogenic enzymes.
While the mechanistic details are not completely elucidated, it is clear that there are species
and tissue differences and even differences among specific FA isomers.
The overall objective of this dissertation was to investigate the molecular mechanisms
of different bioactive FAs on some aspects of lipid metabolism in different lipogenic tissues
using ruminant and non-ruminant animal models. One investigation examined the role of
thyroid hormone responsive spot 14 (S14) protein in mediating the antiobesity effect of CLA
using a mouse model. The S14 gene encodes for a small nuclear protein and is predomi-
nantly expressed in lipid synthesizing tissues; its exact function is not clear, but several lines
of evidence in rodent models suggest that it might be required for normal lipogenesis [8].
Similarly, S14 gene expression was highly correlated with downregulation of mammary li-
pogenesis in lactating dairy cow and body fat deposition in growing mice receiving trans-10,
cis-12 CLA treatment [9]. Therefore, we hypothesize that S14 gene might be essential for
normal lipogenesis in white adipose tissue and, moreover that S14 may be implicated in the
mechanism by which CLA is able to reduce body fat accretion.
A second area investigated in this dissertation involved the ability of LC ω-3 PUFAs to
affect lipid metabolism. Studies involving oral administration of fish oil or purified ethyl
esters of EPA and DHA in both experimental animals and humans have observed a decrease
in serum and hepatic levels of triglycerides, cholesterol and phospholipid [10], and a reduc-
tion in body fat deposition [11]. However, the effect of LC ω-3 PUFAs on the biology of
mammary gland, the major lipid synthesizing organ during lactation, has not been investi-
4gated extensively and to the best of our knowledge the effects on mammary lipogenesis per
se have not been reported. Therefore, a second thesis objective was to examine the effects
of fish oil supplementation on mammary lipogenesis and the expression of lipogenic genes
and transcription factors in mammary and hepatic tissues of lactating mice.
The final investigation of the current dissertation was an examination of the molecu-
lar mechanisms mediating the CLA-induced downregulation of mammary lipid synthe-
sis. There have been several published studies characterizing the cellular changes in CLA-
induced MFD in dairy cow [6]. Other studies have shown that CLA also induces MFD in
lactating ewes [12], but, the molecular basis for MFD, whether induced by diet or CLA sup-
plementation, has not been investigated. Thus, the final thesis objective was to use lactating
ewes as a model and investigate the molecular changes during CLA-induced MFD.
Chapter 2
Literature Review
2.1 Lipogenesis
De novo lipogenesis (DNL) involves the metabolic pathways leading to synthesis of fatty
acids (FAs), which are ultimately esterified with glycerol-3-phosphate to form triglycerides
(TG) [13]. FAs are essential components of all biological membranes and represent an impor-
tant form of energy storage in both animals and plants [14]. As a consequence, the enzymatic
pathways of DNL are present in all living organisms [15] and most tissues synthesize FAs
at low rates that are not under hormonal or dietary regulation [16]. In contrast, the FA syn-
thesis in liver, adipose tissue and lactating mammary gland, the major sites for DNL [17,18],
can occur at rates 10 - 1,000 times those in other tissues and is regulated by diet and hor-
mones [16]. The relative contribution of the lipogenic tissues to total FA synthesis depends
on the species and the physiological status of the animal itself [16, 17]. For example, FA syn-
thesis occurs primarily in the liver of humans and birds. Rodents can synthesize FAs at high
rates in both liver and adipose tissue, whereas in pigs and ruminants, adipose tissue is the
primary site [16, 19]. On the other hand, in lactating mammals the mammary glands are the
major site of DNL with the FA being used for milk fat production. For example, whereas the
liver and adipose tissue contribute about equally to total FA synthesis in the virgin mouse,
by mid-lactation the contribution of the mammary gland accounted for approximately 75%
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of the total rate of FA synthesis which mostly secreted into milk [20].
In non-ruminants, the enzymes involved in the lipogenic pathway include: (i) glucoki-
nase and L-type pyruvate kinase (L-PK) for glycolysis; (ii) ATP citrate lyase (ACYL), acetyl-
coenzyme A carboxylase (ACAC) and fatty acid synthase (FASN) for lipogenesis and long-
chain elongase and stearoyl-coenzyme A desaturases (SCD) catalyzing FA elongation and
desaturation steps; and (iii) glycerol-3-phosphate acyltransferase (GPAT), 1-acylglycerol-3-
phosphate O-acyltransferase (AGPAT) and diacylglycerol O-acyltransferase (DGAT) for TG
synthesis [13].
FAs are synthesized by an extramitochondrial system that is responsible for the com-
plete synthesis of palmitate from acetyl-CoA in the cytosol [21]. The synthesis of FAs de
novo is achieved by the sequential condensation of two-carbon units derived initially from
acetyl-CoA [14]. Glucose is the primary substrate for FA synthesis in most tissues in the
body, including liver, adipose tissue, and mammary gland of non-ruminants [16]. A well
recognized and major metabolic difference between the ruminant and non-ruminant is the
failure of carbon from glucose to contribute to FA synthesis within the tissues of a ruminant,
including mammary gland. This phenomenon is accounted for in part by the negligible ac-
tivity of ACYL and NADP-malate dehydrogenase [19, 21]. Rather, acetate and to a lesser
extent β-hydroxybutyrate, serve as the precursors for FA synthesis in both adipose tissue
and mammary gland of ruminants. Acetate is converted to acetyl-CoA in the cytosol and
this is the principal building block of FA. β-hydroxybutyrate use is more limited as it can
serve only as the first four-carbon primer in the initiation of FA synthesis [22].
The biosynthesis of FAs apart from carbon substrate also requires considerable amounts
of reducing equivalents in the form of NADPH. The cytosolic enzymes which potentially
could be involved in NADPH production are glucose-6-phosphate dehydrogenase (G6PD),
phosphogluconate dehydrogenase (PGD), NADP-malate dehydrogenase and NADP- isoci-
trate dehydrogenase (IDH1) [19,22]. It takes two NADPH for each two carbon addition from
malonyl-CoA. In rats, the first two enzymes of the pentose phosphate pathway (G6PD and
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PGD) contribute about one-half of the reducing power for FA synthesis with the remain-
der coming from the malate transhydrogenation cycle via NADP-malate dehydrogenase. In
ruminants, NADP-malate dehydrogenase is negligible and its contribution of NADPH is
replaced by cytosolic IDH1 [19, 22].
ACAC is a complex enzyme system which catalyzes the carboxylation of acetyl-CoA to
malonyl-CoA, the rate-limiting step in FA synthesis. There are two ACAC forms, acetyl-
coenzyme A carboxylase alpha (ACACA) and acetyl-coenzyme A carboxylase beta (ACACB),
encoded by two different genes. ACACA is expressed in all cell types but is found at its
highest levels in the lipogenic tissues [23]. The activity of ACACA is regulated in a com-
plex fashion. In the short term ACACA is regulated through allosteric mechanisms with
cellular metabolites possessing positive (citrate) or negative effect (malonyl-CoA and long-
chain acyl-CoA), and reversible activation/deactivation via phosphorylation on a number of
specific serine residues [24]. On the long term, ACACA is regulated through complex tran-
scriptional regulation involving the presence of multiple promoters and splice variants that
are expressed in a tissue and signal specific manner [23].
The entire pathway of palmitate synthesis from malonyl-CoA in mammals is catalyzed
by a single, homodimeric, multifunctional protein, FASN [25]. The synthesis of palmitate
is carried out by a very complex overall reaction that involves sequential condensation of
seven two-carbon units derived from malonyl-CoA to the primer acetyl moiety derived from
acetyl-CoA [26]. Contrary to what is observed in rodent mammary gland, FASN in rumi-
nant mammary tissue synthesizes short-and medium chain fatty acids (MCFAs) without the
implication of a thioesterase II [27]. In addition to being able to load acetyl-CoA, malonyl-
CoA, and butyryl-CoA, ruminant FASN contains a loading acyltransferase whose substrate
specificity extends to up to C12, with the result that it is able to load and also release these
short-and MCFAs [28]. This mechanism is specific to the lactating mammary gland, whereas
the product of FASN in other lipogenic tissues is predominantly C16:0 for both ruminants
and non-ruminants [19, 22, 29].
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SCD catalyzes a rate-limiting step in the synthesis of unsaturated FAs through ∆-9 desat-
uration, introducing a cis double bond. The principal product of SCD1 is oleic acid, which is
formed by desaturation of stearic acid. Although the kinetics differ, SCD1 is able to act on a
spectrum of fatty acyl-CoA substrates, including FAs ranging from C14 to C19. For example,
palmitoleoyl-CoA and oleyl-CoA are synthesized from palmitoyl-CoA and stearoyl-CoA,
respectively, by the action of SCD1 [30]. In addition, in bovine mammary gland, SCD1 is
responsible for the synthesis of the major portion of two CLA isomers found in milk fat, cis-
9, trans-11 CLA and trans-7, cis-9- CLA [31, 32]. Four SCD isoforms, SCD1 through SCD4,
have been identified in mouse. In contrast, only 2 SCD isoforms, SCD1 and SCD5, have been
identified in human and cow.
The first step in TG biosynthesis is the esterification of glycerol-3-phosphate in the sn-
1 position; this reaction is catalyzed by GPAT. Two isoforms of GPAT have been identified
in mammals and these differ in their subcellular location (mitochondrial vs. endoplasmic
reticulum) [23]. In rodents, both isoforms have a role in the TG synthesis in the liver and
adipose tissue [33]. The second step of TG synthesis is committed by AGPAT. AGPAT has a
greater affinity for saturated fatty acyl-CoA in the order C16 > C14 > C12 > C10 > C8, which
is in accordance with the observed high proportion of medium- and long-chain saturated
FAs at the sn-2 position in milk, with palmitate as the major FA (representing 43% of the
total palmitate found in triacylglycerol) [23]. The third enzyme, DGAT, is located on the
endoplasmic reticulum membrane. DGAT is the only protein that is specific to triacylglycerol
synthesis and therefore may play an important regulatory role [33].
2.2 Thyroid Hormone Responsive Spot 14 and Lipogenesis
The thyroid hormone responsive spot 14 (S14) gene codes for a 17-kDa acidic protein that
lacks any well-recognized functional motifs [8]. However, several lines of evidence suggest
that this protein may be involved in lipogenesis. For example, S14 mRNA has been de-
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tected predominantly in lipogenic tissues [34]. In addition, levels of hepatic S14 mRNA are
extremely low in fetal and newborn rats but increase at the time of weaning [35] and the
increase corresponds to a similar increase in lipogenesis and lipogenic enzymes [8]. More-
over, alterations in the expression of S14 in lipogenic tissues also correspond to changes in
the expression of other lipogenic enzymes in other physiological situations. On the other
hand, S14 gene expression in liver is controlled by a wide variety of hormones and dietary
factors in parallel with the major lipogenic enzyme genes [36]. A particularly striking as-
pect of S14 expression is its rapid and robust response to thyroid hormone (TH) [37] and
carbohydrate [38], which made expression of S14 very useful in the study of TH action [8].
The direct role of TH and carbohydrate in regulation of the expression of S14 gene, has been
confirmed by the identification of several TH [39] and a carbohydrate [40] response elements
in the S14 gene promotor region. In addition, hepatic S14 mRNA abundance is reduced in
diabetic rats and insulin administration to streptozotocin-induced diabetic rats restored lev-
els of hepatic S14 mRNA to normal within 4 h [41]. Moreover, in coordination with other
lipogenic genes, administration of long-chain PUFAs to rats downregulated the abundance
of S14 mRNA [42].
To better understand the role of S14 in lipogenesis, hepatocytes were transfected with
an S14 antisense oligonucleotide. Interestingly, the transfected cells showed lower levels of
lipogenesis, compared with controls, and this was associated with a diminished immunore-
activity of ACYL and FASN, reduced induction of malic enzyme by T3 and carbohydrate,
and decreased malic enzyme mRNA abundance [43]. Furthermore, an experiment using
siRNA to knock down S14 expression in breast cancer cells showed that S14 was required
for lipogenesis [44].
The results obtained from the oligonucleotide model are supported by studies with mice
that had a knockout of the S14 gene. The mammary lipogenic rate of knockout dams was
decreased by 62% compared to wild-type dam and this correspond to a similar reduction
in the de novo synthesis of FAs [45]. However, despite the lower production of FAs and the
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decreased rate of lipogenesis, there was no reduction in the activity and mRNA abundance of
key enzymes involved in lipogenesis (FASN,ACACA). These data indicate that the regulatory
impact of S14 on lipogenesis does not occur by altering the transcription of the rate-limiting
lipogenic enzymes [8]. Indeed, malonyl-CoA, the substrate of the FASN reaction, has been
shown to be increased in the mammary gland of the S14 knockout animal which suggests
that the defect in lipogenesis occurs because of an in vivo decrease in FASN activity [8].
Thus, the S14 protein may act as an allosteric regulator of the in vivo activity of FASN [8].
Moreover, the lack of S14 in liver did not affect hepatic lipogenesis which suggests that there
may be another related protein that can compensate for the lack of S14 [8]. Indeed, a paralog
of S14 has been identified and given the name S14 related protein (MIG12) [45]. Interestingly,
MIG12 was less abundant in mammary gland compared with liver which may explain the
contrast in the lipogenic phenotype between both organs in the knockout animal [45]. Using
small interfering RNA to simultaneously reduce levels of S14 and MIG12 in cultured primary
hepatocytes, the rates of lipogenesis were decreased by approximately 65% in cells treated
with insulin and high glucose. Interestingly, expression of either S14 or MIG12 gene products
was sufficient to fully restore normal lipogenesis [36].
2.3 Bioactive Fatty Acids
2.3.1 Conjugated Linoleic Acid
CLA is a generic term used to describe positional and geometric isomers of linoleic acid (cis-
9, cis-12 octadecadienoic acid). In CLA isomers, the two double bonds are located adjacent to
one another rather than being separated by an interceding carbon as occurs in most PUFAs.
The two double bonds in CLA can vary in location ( for example 8 and 10, 9 and 11, 10 and
12, or 11 and 13) and the double bonds can be any combination of cis or trans configuration
[32, 46].
CLA originate from two sources - industrial or natural [32]. The CLA from industrial
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sources originates from the partial hydrogenation of vegetable oils. Natural sources are CLA
isomers produced by rumen bacteria as intermediates in the biohydrogenation of dietary
PUFAs. For this reason, CLA is found naturally mainly in ruminant meat and dairy prod-
ucts. Although there are over 20 different CLA isomers found in ruminant-sourced foods,
the cis-9, trans-11 CLA , also known as rumenic acid, is the most abundant isomer accounting
for 75-90% of total CLA [32]. Trans-7, cis-9 CLA is the second most common isomer, repre-
senting about 10%. Other CLA isomers generally comprise only 1-2% each of total CLA in
ruminant fat [32, 47, 48]. After formation in the rumen, most cis-9, trans-11 CLA is biohydro-
genated by rumen microorganisms to trans-11-octadecenoic acid (vaccenic acid) and then to
stearic acid. However, some rumenic acid does pass from the rumen and is absorbed. It
was originally thought that this was the source of rumenic acid in ruminant fat, but subse-
quent work showed the major source was endogenous synthesis [32]. Endogenous synthesis
involves vaccenic acid which is also absorbed and then may be converted by SCD1 within
mammalian cells back to cis-9, trans-11 CLA by incorporating a cis double bond in posi-
tion 9. Likewise, trans-7, cis-9 CLA also arises predominantly from endogenous synthesis
via stearoyl-coenzyme A desaturase 1 (SCD1) with the substrate being trans-7-18:1, another
intermediate produced in rumen biohydrogenation [49].
The CLA content of ruminant-sourced food is variable and depends on several factors,
including season, the animal’s breed, nutritional status and age of the cows [50]. However,
diet is the major factor affecting ruminant fat content of CLA with the proportion of CLA
generally ranging from 0.34% to 1.07% of FAs in dairy products, and from 0.12% to 0.68%
of the total FAs in raw or processed beef products [32]. Rumenic acid has been shown to
have anticarcinogenic and antiatherogenic effects in biomedical studies with animal models.
In addition several of the CLA isomers of minor concentration in ruminant fat also have
biological activity. In particular, trans-10, cis-12 CLA is a potent inhibitor of body fat accretion
and milk fat synthesis as will be discussed in later sections.
In addition to natural sources, chemical synthesis of CLA has been achieved to produce
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products with different CLA isomers [51]. These laboratory methods of chemical synthe-
sis of CLA isomers typically involve a partial hydrogenation of linoleic acid [48]. Initial
methods resulted in CLA preparations that had four isomers (trans-8, cis-10; cis-9, trans-11;
trans-10, cis-12 and; cis-11, trans-13) and these were used in many biomedical studies with
animal models. Subsequently, the method of partial hydrogenation was modified to produce
a product that consisted mainly of two isomers [32, 51]. CLA content in these preparations
was about 90% and this was made up of 50:50 mixture of cis-9, trans-11 CLA and trans-10,
cis-12 CLA with less than 5% of the total CLA being made up of trace amounts of other CLA
isomers. Over the last decade, this mixture of cis-9, trans-11 CLA and trans-10, cis-12 CLA
has been used in most experimental studies and this is also the CLA mixture that is com-
mercially available as a supplement for humans. However, recent evidence indicates that
both isomers exhibit significant biological activities, which in some cases are similar but in
other cases the two isomers have opposite biological effects. With technology advancements,
enriched or purified cis-9, trans-11 and trans-10, cis-12 CLA preparations have become com-
mercially available in recent years, so that the effects of individual isomers can be examined
in health-related disorders [48].
2.3.2 Omega-3 Polyunsaturated Fatty Acids
The ω-3 FAs are PUFAs where the first double bond is three carbon atoms from the methyl
terminal; this results in distinct properties that separate these FAs from the more common
ω-6 or ω-9 FAs. The long chain PUFAs of the ω-3 series docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) represent a unique class of food constituents that show a wide
range of functions in biological systems. The effects include the ability to modulate gene ex-
pression [52], inflammatory processes [53] and cellular membrane structure and function as
well as modulate signaling pathways involved in normal and pathological cell functions [54].
Recent epidemiological and clinical studies with humans and biomedical studies using ani-
mal models indicate that food sources of EPA and DHA may be useful for reducing the risk of
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coronary heart disease and atherosclerosis, treating inflammatory conditions and preventing
certain types of cancer [5, 55].
PUFAs in general are fundamental components of phospholipids in cellular membranes.
They are usually located in the sn-2 position, whereas saturated or monounsaturated FAs are
usually bound in the sn-1 position of phospholipid molecules [11]. The relative abundance
or ratio between the long chain ω-6 (arachidonic acid (AA)) and ω-3 (EPA and DHA) FAs in
cell membranes depends on their supply in the diet and the conversion (elongation and de-
saturation) of their precursors, linoleic acid (LA) and α linolenic acid (ALA), respectively. LA
and ALA are considered essential FAs and must be supplied in the diet as the body can not
synthesize them in adequate amounts [56]. Although conversion of ALA to LC ω-3 PUFAs
is important to maintain constant levels of EPA and DHA [57], emerging evidence suggests
that the process is relatively inefficient; in human only about 5% of ALA is converted to EPA
and less than 0.5% is converted to DHA [56]. On the other hand, the conversion of LA to AA
is much more efficient [58]. Therefore, the tissue content of LC ω-3 PUFAs largely depends
on the exogenous supply of EPA and DHA.
Fish are the primarily source of LC ω-3 PUFAs and their levels of EPA and DHA vary
according to the fish species, season, fishing area, and age and gender of the fish [59]. EPA
and DHA can also be obtained from other sources such as marine microalgae, the primary
producers of EPA and DHA, and krill oil, extracted from marine invertebrates in the zoo-
plankton [59]. Most dietary ω-3-rich fish oils and many supplements provide EPA and DHA
as esterified in a TG. On the other hand, supplementation with free FAs and FA esters can
provide higher levels of EPA and DHA, but the free FAs form can cause gastrointestinal
complaints [59]. Thus, esterified forms of EPA and DHA have been developed and the ethyl
esters are the most common supplement form of EPA and DHA due to their greater sta-
bility and the fact they avoid the potential toxic effects of methanol released from methyl
esters [60]. The TG and the ethyl ester forms of EPA and DHA appear to have slight dif-
ferences in absorption rate, but the total levels of EPA and DHA incorporated into plasma
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lipids have been shown to be equivalent for both forms [60, 61]. Moreover, ethyl esters of
EPA and DHA have also been associated with positive health outcomes in research trials
and are being utilized in therapeutics [59].
The LC ω-3 PUFAs are able to markedly affect lipid metabolism in liver and to a lesser
extent adipose tissue. Studies involving oral administration of fish oil or purified ethyl esters
of EPA and DHA in both experimental animals and humans report a decrease in serum and
hepatic levels of TG, serum concentration of cholesterol and phospholipid [10] and a reduc-
tion in body fat deposition [11, 62]. Although mechanistic details are not fully understood,
the effects of LC ω-3 PUFAs in liver involve the regulation of the activity of metabolic nuclear
receptors which results in repartitioning of metabolic fuel (i.e, FAs) away from TG synthesis
and storage toward oxidation; the net effect is a decrease in the substrate available for very
low density lipoprotein synthesis and secretion [63].
The effect of LC ω-3 PUFAs on the biology of mammary gland, the major lipid synthe-
sizing organ during lactation, has not been investigated extensively and to the best of our
knowledge the effect of LC ω-3 PUFAs on mammary lipogenesis per se has not been re-
ported. Investigations of FO or LC ω-3 PUFAs on the milk FA composition in lactating rats
indicate a trend toward an increase in the proportion of MCFAs in milk fat relative to the
control diets [64–68]. Most diets are devoid of MCFAs so their presence in milk fat may be
indicative of mammary de novo FA synthesis (DFAS). However, these experiments were not
designed specifically to address effect on rates of de novo FA synthesis (DFAS) and an in-
crease would be contrary to the well established downregulation effect of LC ω-3 PUFAs on
the hepatic lipid synthesis. Moreover, when lactating cow were abomasally infused with FO,
EPA and DHA content of milk fat increased indicating these LC ω-3 PUFAs were taken-up
and utilized by the mammary gland, but milk fat yield was unaffected [69].
In addition to their ability to modulate the activity and/or abundance of nuclear re-
ceptors, many effects of LC-PUFAs depend on the formation of their active metabolites,
eicosanoids and other lipid mediators, which have diverse physiological effects [11]. Follow-
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ing cell activation by inflammatory stimuli, PUFAs in membrane phospholipids of various
cell types are released by phospholipase A2 and converted to eicosanoids by cyclooxyge-
nases (COX) and the lipoxygenases (LOX) [58]. Metabolism of the ω-6 AA by the COX path-
way produces prostaglandins (PG) and thromboxanes (TX), while leukotrienes (LT) are the
end products of the LOX pathway [58]. Many of these AA-derived eicosanoids are highly
pro-inflammatory. On the other hand, the ω-3 FA EPA is metabolized by mammalian cells
through the same COX and LOX pathways to form a different series of PG, and LT which
are much less pro-inflammatory and can even have opposing effects as compared to their
counterparts derived from AA [53]. Thus, inhibition of the formation of AA-derived pro-
inflammatory mediators by competing with AA for the COX and LOX enzymes is thought
to be a major mechanism underlying the antiinflammatory effect of ω-3 FA [70]. Moreover,
recent studies have discovered resolvin and protectins, EPA and DHA derivatives with po-
tent antiinflammatory properties [71].
In addition to the competition for the COX and LOX enzymes, ω-6 and ω-3 FAs also com-
pete for the enzymes involved in the elongation and desaturation of these FAs as well as
their incorporation into phospholipids. When one type of FA predominates in cell mem-
brane phospholipids, it is the major substrate for these enzymes. For example, a flush of
ω-3 ALA or EPA into cells would dramatically reduce the ω-6 LA and AA content of cellular
phospholipids [58]. Thus, dietary supply and the balance between these FAs influences the
composition of cell membrane phospholipids, and this modulates the production of different
eicosanoids thereby affecting the physiological process [53] . For this reason, maintaining a
balance of ω-6 and ω-3 PUFAs is important for optimal biochemical balance in the body [58].
Moreover, a portion of the metabolic effects on LC ω−3 PUFAs in the liver, and possibly
in other tissues, is mediated by the stimulation of AMP-activated protein kinase (AMPK),
a metabolic sensor controlling intracellular metabolic fluxes including the partitioning be-
tween lipid oxidation and lipogenesis [72]. Phosphorylation of ACAC by AMPK leads to
an inhibition of enzyme activity, resulting in a decrease in malonyl-CoA content which is a
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key lipogenic intermediate that also inhibits mitochondrial carnitine palmitoyltransferase-1
(CPT-1). Thus, AMPK inhibits lipogenesis while stimulating β-oxidation.
2.4 Transcriptional Control of Lipogenesis by PUFAs
Metabolic regulation is one of the most remarkable features of living organisms. Of thou-
sands of catalyzed reactions that can take place in a cell, there is probably not one that es-
capes some form of regulation [73]. It is commonly accepted that metabolic regulation in
complex organisms relies on three main types of control. The first corresponds to the classic
allosteric control of the activity of a key enzyme along a metabolic pathway triggered by the
binding of an activator or inhibitor, which often is the substrate or product of the enzyme it-
self. The second mechanism involves various translational modifications such as proteolytic
cleavage, phosphorylation, glycosylation and acetylation, which may shift the equilibrium
between an inactive and active forms of the enzyme within seconds and/or affect protein
stability. The third mechanism is transcriptional regulation, which affects the level of expres-
sion of key enzymes and is effective on a longer time scale. It is clear that the regulation of
metabolic process involve a coordination of these various mechanisms [74].
This thesis focuses on transcriptional regulation and understanding the transcriptional
control of metabolism relies on three complementary pieces of information: 1) events up-
stream of transcriptional activity, which define the signals involved and their route to the
nucleus; 2) the molecular mechanisms by which transcription factors operate; and 3) events
downstream of transcriptional activity, which depend on the groups of genes that are tar-
geted and how additional signals are generated to reach the dynamic equilibrium of home-
ostasis [74]. The transcription regulation of a set of genes is mediated through the action on
nuclear receptors; activation induces a conformational change in the receptor that promotes
an exchange of regulatory factors interacting with the nuclear receptor and hence activate
the transcription of the target genes [74]. Many transcription factors have been identified to
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regulate the expression of enzymes involved in the lipogenic pathway which include sterol
regulatory element binding transcription factor (SREBF), peroxisome proliferator-activated
receptor (PPAR), liver X receptor (LXR), hepatocyte nuclear factor 4 (HNF-4), and retinoid X
receptor (RXR).
2.4.1 Transcription Factors Regulating Lipogenesis
2.4.1.1 SREBF
SREBFs are a family of transcription factors which function as global regulators of lipid syn-
thesis (see reviews [75,76]). Two genes, SREBF1 and SREBF2, encode three proteins of SREBF
family. The SREBF2 gene encodes a single protein that has approx. 50% homology with
SREBF1. As a result of alternative splicing and the use of alternative promoters, SREBF1 gene
encodes two proteins, SREBF1-a and SREBF1-c, that differ only in the length of the amino ter-
minal transactivation domain [75]. SREBFs are synthesized and located on the endoplasmic
reticulum endoplasmic reticulum (ER) as membrane-bound precursors that require cleavage
by a two-step proteolytic process in order to release their amino-terminal domain (nuclear
SREBF) [76]. The SREBF cleavage-activating protein (SCAP) functions as a cholesterol sen-
sor. When the cellular cholesterol levels are depleted, SCAP binds to and escorts SREBFs
to the golgi apparatus, where the site 1 and site 2 proteases cleave the SREBF. The cleav-
age form of SREBF is referred to as nuclear SREBF or mature SREBF; it enters the nucleus
and in conjunction with other DNA binding proteins, binds to a sterol regulatory element
in the promotor region of target genes with subsequent recruitment of coactivator proteins
to initiate transcription. Upon restoration of cellular cholesterol, insulin-induced gene (IN-
SIG), another key regulator of ER membrane proteins, traps and retains the SREBF–SCAP
complex at the ER thereby inhibiting SREBF trafficking to the golgi for cleavage to form
nuclear SREBF. SREBF1-c is also subject to the SCAP–INSIG cleavage regulation system de-
scribed above for all SREBFs, but it is not strictly under sterol regulation [76]. SREBF1-c,
SREBF1-a and SREBF2 belong to the same family, but there are distinct differences regarding
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tissue distribution and their target genes [76, 77]. SREBF2 mRNA is expressed at a similar
level in most tissues but the relative levels of SREBF1-a and SREBF1-c differ significantly.
Whereas in culture cells, expression of genes encoding SREBF1-a > SREBF1-c, the ratio of
SREBF1-c : SREBF1-a varies significantly in animal tissues being 9, 3, or 0.1 in liver, adipose
tissue or spleen, respectively [78]. However, recent studies demonstrated that the relative
expression of SREBF-1a, -1c, and -2 in vivo is complex and can be affected by the nutri-
tional and hormonal status of the animal [75]. Furthermore, the proteolytic cleavage of the
precursor SREBF1 and SREBF2 can be regulated independently [75]. On the other hand,
while SREBF target genes identified to date include many that are involved in the control of
cholesterol synthesis, FA synthesis, TG synthesis and glucose metabolism [75, 77] , SREBF2
and SREBF1-a show a tendency toward activation of genes involved in cholesterol synthe-
sis more than those involved in the pathways of FA synthesis . Overexpression of mature
SREBF2 or SREBF1-a transcriptionally activates genes involved in both cholesterol and FA
synthesis, although, the ratio of cholesterol : FA synthesis is greater in the SREBF2 than in the
SREBF1-a overexpressing animals [75]. In contrast, SREBF1-c acts more specifically on genes
involved in FA synthesis. It is highly expressed in the liver and the white adipose tissue and
is sensitive to multiple regulatory signals. Furthermore, overexpression of SREBF1-c and
formation of the nuclear form strongly increases the TG content of the liver, with no parallel
accumulation of cholesterol [74].
The transcriptional effect of insulin, long thought to be the main inducer of glycolytic and
lipogenic gene transcription, is mediated by SREBF1-c. Insulin stimulation of the transcrip-
tion of SREBF1-c and the formation of the nuclear SREBF1-c, together with a signal derived
from glucose, result in enhanced transcription of genes involved in both lipogenesis and
glucose metabolism such as the genes encoding ACAC, FASN, Elovl-6, and SCD. Therefore,
most of the lipogenic effects of insulin are dependent on the induced expression of SREBF1-c
and the subsequent increased expression of genes for key enzymes in the FA synthesis path-
way.
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Although the post-transcriptional maturation of SREBFs is an important regulatory event,
the transcriptional regulation of SREBF1-c expression parallels the activity of the transcrip-
tion factor [74]. SREBF1-c expression is also stimulated by the LXR, via two LXR binding
sites present in the SREBF1-c promoter [74]. In addition, SREBF1-c expression is induced by
itself.
2.4.1.2 PPAR
PPARs are key transcriptional factors that play a central role in regulating the oxidation
and storage of dietary lipids, essentially by serving as sensors for FAs and their metabolic
intermediates [79]. PPARs control expression of various genes that are crucial for lipid and
glucose metabolism. To date, three major types of PPAR, have been identified, namely α, γ,
and β/δ [79]. Each type is encoded by a separate gene and they vary in ligand specificity and
tissue distribution; hence these isoforms serve different biological functions [79]. Natural
FAs and the fibrate class of hypolipidaemic drugs are known activators of PPARs [79].
The gene transcription mechanism is identical in all PPAR subtypes [79]. PPARs form het-
erodimers with (RXR α) [80] and bind to the specific DNA sequence designated PPRE (per-
oxisome proliferator response elements) present in the promoter region of PPAR-regulated
genes. Binding of exogenous (drugs) or endogenous (FAs, PG, etc.) ligands [79] is essen-
tial for the PPAR heterodimer to initiate a complicated transcription process, which includes
the dissociation of corepressor protein complex and association or recruitment of coactivator
protein complexes [81]. This results in the increase in transcription activities of various genes
involved in diverse biological processes. In addition, PPARs can be activated by phosphory-
lation and the PPAR:RXR heterodimer can be activated by RXR ligands [82]. These different
activation mechanisms, which can act concomitantly, illustrate the capacity of fine-tuning
that allows for the orchestration by PPAR actions [74].
PPARα serves as the master regulator of FA oxidation in liver [81] in which it controls
a comprehensive set of genes that regulate most aspects of lipid catabolism [74]. It also
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stimulates the cellular uptake of FAs by increasing the expression of the FA transport protein
and FA translocase [83]. PPARα is expressed in numerous tissues in rodents and humans
including liver, kidney, heart, skeletal muscle and brown fat [84, 85]. On the other hand,
PPARγ is an important transcription factor involved in adipogenesis, glucose homeostasis
and lipid metabolism; it is considered to be the master architect of adipocyte differentiation
and is required for adipose tissue formation in vivo [86]. PPARγ has two isoforms, PPARγ1,
and PPARγ2, encoded from the same gene by selective usage of two distinct promoters and
alternate splicing [87]. PPARγ1 is found in a broad range of tissues, whereas PPARγ2 is
restricted to adipose tissue [79]. PPARγ target genes include adipocyte FA binding protein,
LPL, and LXRα. In adipose tissue, activation of these genes by PPARγ promotes fat storage
and reduces serum lipid levels [86]. The third type, PPARβ/δ is expressed in most tissues
and is also responsible for widespread effects on energy oxidation mainly in extrahepatic
tissues [88].
2.4.1.3 CHREBP
Carbohydrate response element binding protein (ChREBP) is a transcription factor that me-
diates the glucose effect on both glycolytic and lipogenic gene expression [89]. ChREBP
is predominantly expressed in liver, kidney, white adipose tissue and brown adipose tis-
sue [89]. Under basal conditions ChREBP is localized in the cytosol, and its nuclear translo-
cation is rapidly induced under high glucose concentrations. Nuclear translocation and
DNA binding of ChREBP is controlled by dephosphorylation of several serine and threo-
nine residues [89]. Glucose- or carbohydrate-response elements (ChoREs) that mediate the
transcriptional response of glucose have been identified in the promoters of most lipogenic
genes including FASN and ACAC [90, 91]. ChREBP does not act alone, but instead func-
tions in a heterodimeric complex with the transcription factor MAX-like protein X (MLX).
Together, these two transcription factors bind to and activate transcription of glycolytic and
lipogenic genes containing a ChRE.
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ChREBP is considered to be a key determinant of lipid synthesis in liver [92] where it
acts as a central modulator of FA concentrations in liver by transcriptionally controlling the
key enzymes in the lipogenic program (ACAC, FASN, SCD-1) and TG synthesis (GPAT) [89].
The liver-specific inhibition of ChREBP markedly affects the expression of ACACA, FASN
and SCD1 [89] and ChREBP gene knockout mice exhibit glucose and insulin intolerance and
have impaired glycolytic and lipogenic pathways in liver [93].
2.4.1.4 LXR
LXR regulates the expression of genes involved in bile acid synthesis, reverse cholesterol
transport, clearance of blood lipids, lipogenesis, and glucose uptake [94]. There are two
LXR receptors, LXRα and LXRβ. Whereas LXRβ has a ubiquitous tissue distribution, LXRα
predominates in the liver, adipose tissue, and macrophages [86]. The two forms appear
to respond to the same natural and synthetic ligands, and the natural LXR ligands include
physiological concentrations of sterol metabolites. LXR/RXR heterodimers are constitutively
nuclear and bound to LXR response elements in the promotors of regulated genes. More than
a dozen target genes for LXR have been identified, and many of them are integral parts of
the cholesterol and FA metabolic pathways [86]. LXRα-null mice show reduced expression of
the major lipogenic regulators in the liver including SREBF1-c, FASN, and SCD1 [95]. Giving
synthetic LXR ligands to mice triggers the lipogenic program and results in elevated TG
levels in the plasma and liver [96].
2.4.1.5 XBP1
A recent report has suggested that X-box binding protein 1 (XBP1) is a novel transcription
factor governing hepatic lipogenesis. XBP1 deficiency resulted in profound compromise
of de novo hepatic lipid synthesis, leading to concomitant decreases in serum TG, choles-
terol, and free FAs without causing hepatic steatosis. XBP1 was induced upon feeding high-
carbohydrate diet and directly activated the transcription of key lipogenic genes involved
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in hepatic FA synthesis [97]. XBP1 is a key regulator of the mammalian unfolded protein
response (UPR) or ER stress response [98]. Accumulating evidence suggests that UPR may
be implicated in the regulation of cellular lipogenesis playing an important role in both FA
synthesis and cholesterol metabolism [99].
UPR is activated under situations where accumulation of abnormally folded proteins or
unassembled subunits occurs in the ER [100, 101]. UPR functions to restore the ER home-
ostasis by reducing the amount of proteins translocated into the ER lumen, increasing retro-
translocation and degradation of ER-localized proteins, and inducing transcription of com-
ponents of the ER machinery involved in folding, quality control, redox and lipid biogene-
sis [100, 101]. Activation of the UPR has cytoprotective effects and allows for cell survival
under moderate ER stress conditions. However, prolonged or severe ER stress can lead to
proapoptotic signals [102].
The UPR involves three integrated pathways that are activated through the ER trans-
membrane proteins; inositol-requiring 1 (IRE1) α, PKR-like ER kinase (PERK) and activating
transcription factor 6 (ATF6) [100,102]. In a well-functioning and “stress-free” ER, these three
transmembrane proteins are bound by a chaperone, glucose-regulated protein (GRP78), in
their intraluminal domains and rendered inactive [99]. Under ER stress conditions, dissoci-
ation of GRP78 from the ER luminal domains of IRE1α, PERK and/or ATF6 allows them to
be activated. [101].
Upon ER stress, the proximal sensor and endoribonuclease IRE1α induces unconven-
tional splicing of XBP1 mRNA to generate a mature mRNA encoding an active transcription
factor, XBP1s [97,100,101]. XBP1s, alone or in conjunction with ATF6α, launches a transcrip-
tional program to produce chaperones and proteins involved in ER biogenesis, ER-associated
protein degradation, and phospholipid synthesis [99] which leads to expansion of the ER
membrane, a structural hallmark of the UPR [100].
All three UPR pathways have been reported to be involved in the regulation of lipid
metabolism [101]. In addition to XBP1, via IRE1α pathway, the UPR transducer ATF6 was
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also involved in phospholipid biosynthesis and ER expansion as well as hepatic lipid home-
ostasis associated with acute ER stress. ATF6α knockout mice displayed no obvious pheno-
type under normal conditions but showed profound hepatic steatosis under acute ER stress
induced by tunicamycin challenge [101]. The UPR branch mediated through PERK/eukaryotic
initiation factor 2 α (eIF2α) has also been implicated in regulating lipogenesis. In the high fat-
fed mice, PERK-mediated eIF2α phosphorylation was crucial for the expression of lipogenic
genes and the development of hepatic steatosis [101]. In addition, UPR has been shown to
promote the proteolytic cleavage of SREBF (1c and 2) transcription factors leading to up-
regulation of FA and cholesterol synthesis, respectively [100, 101]. In fact, SREBFs may be
critical mediators in the integration of lipid metabolism with the UPR [99]. Conditions such
as hyperhomocysteinemia and high alcohol consumption can lead to hepatic steatosis and
have been linked to ER stress-induced SREBF1-c activation [102]. Consistent with this ob-
servation, overexpression of GRP78, the master negative regulator of the UPR, in the liver
of obese (ob/ob) mice can inhibit SREBF1-c cleavage and the expression of SREBF1-c and
SREBF2 target genes [101].
In a related vein, PERK-deficient mammary epithelial cells in mice have an altered FA
content of milk due to the lack of expression of genes involved in FA synthesis, such as
FASN, ACYL, and SCD1 [99]. SREBF1 expression was significantly downregulated in the
PERK-deficient mammary gland cells; therefore, PERK-mediated UPR pathway likely regu-
lates SREBF1-related mammary de novo lipid synthesis [101]. Additionally, a recent study
demonstrated that the IRE1α/XBP1 UPR pathway is indispensable for adipogenesis [101].
XBP1-deficient mouse embryonic fibroblasts and 3T3-L1 cells with XBP1 or IRE1α knock-
down exhibit profound defects in adipogenesis. All together, these reports confirmed crucial
roles of the UPR pathways in lipogenesis and the pathogenesis of lipid-associated metabolic
disease [101].
2.4 Transcriptional Control of Lipogenesis by PUFAs 24
2.4.2 PUFA Regulation of Transcription Factors
2.4.2.1 SREBF
FAs have been shown to regulate the nuclear abundance of SREBF; however, there is no ev-
idence for FA binding directly to SREBF1 or SREBF2 [94]. A high carbohydrate/low fat diet
has been shown to induce the expression of several lipogenic and glycolytic enzymes, includ-
ing ACAC, FASN, SCD1, GPAT, ACYL, pyruvate kinase, malic enzyme, S14 and G6PD. Such
changes in gene expression are likely the result, at least in part, from the insulin-dependent
activation of SREBF1-c. In contrast, addition of PUFAs to rodent diets results in a decline
in the mRNAs encoding these same genes [75]. Recent studies with mice indicate that di-
etary PUFAs repress the hepatic cleavage of SREBF1 to form nuclear SREBF1, but SREBF2
cleavage is unaffected [75]. Consequently, dietary PUFAs result in a decline in the level of
mature, nuclear SREBF1 and the mRNAs for SREBF1 target genes [75]. Moreover, PUFAs
suppression of SREBF1 nuclear abundance accounts for much of the well characterized sup-
pression of de novo lipogenesis by dietary PUFAs [103]. This decline in the expression of
SREBF1 target genes was not observed when PUFAs were fed to transgenic mice that con-
stitutively express mature SREBF1-a [104]. The results of these studies indicate that PUFAs
likely prevent the cleavage/maturation of SREBF1. This phenomenon is seen in livers of
animals fed PUFAs-containing diets, as well as in primary hepatocytes and some, but not
all, SREBF1-c expressing cells lines treated with PUFAs [94]. In addition, PUFAs selectively
suppress hepatic levels of SREBF1 mRNAs ( 1a and 1c), but not SREBF2; this reduction has
been attributed to an inhibition of the transcription of the SREBF1 gene and an enhanced
turnover of the mRNA encoding SREBF1 [94].
The effect of PUFAs on nuclear abundance of SREBF can be explained, in part, by their
effect on the cellular cholesterol homeostasis. Increasing cellular levels of cholesterol, as
well as factors that affect intracellular cholesterol distribution, influence nuclear levels of
SREBF [105]. In this regard, treatment of cells with unsaturated FAs leads to a PUFAs en-
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richment in membrane phospholipids and sphingolipids, and this promotes redistribution
of cholesterol from the plasma membrane to the endoplasmic reticulum. In addition, sphin-
gomyelinase activity is stimulated, leading to the release of ceramide, an important signaling
molecule [105]. These events have been shown to suppress proteolytic processing of precur-
sor SREBF and this correspond to a decline in nuclear SREBF levels and SREBF-mediated
gene expression [94].
2.4.2.2 PPAR
PPAR is the only well-accepted FA-regulated nuclear receptor. All PPAR subtypes (α, γ, and
β/δ) bind saturated and unsaturated FAs ranging in length from 16–20 carbons. FA binding
initiates a sequence of events that leads to activation of multiple genes involved in FA trans-
port, binding and metabolism [103]. Certain FAs, however, are more effective than others at
activating PPAR . Structural studies have established that EPA is both a ligand and a robust
activator of PPAR while DHA and docosapentaenoic acid (22:5 ω-3) are weak PPARα ac-
tivators [103]. Challenging cells with EPA, significantly changes intracellular non-esterified
fatty acids (NEFA) composition and promotes a robust response in PPARα target genes [106].
The changes in intracellular 20:5 ω-3 are recognized by PPAR and mechanisms are initiated
to prevent excessive accumulation of this highly unsaturated FAs; this supports the con-
cept that PPARs are monitors of intracellular NEFA composition and respond accordingly
to induce metabolic pathways that minimize damage brought on by excessive intracellular
NEFA [103].
2.4.2.3 CHREBP
ChREBP has been shown as central for the coordinated inhibition of glycolytic and lipogenic
genes by PUFAs [107]. In both primary cultures of hepatocytes and in liver in vivo, PU-
FAs such as LA, EPA, and DHA suppresses ChREBP activity by increasing its mRNA decay
and by altering ChREBP protein translocation from the cytosol to the nucleus. The PUFAs-
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mediated alteration in ChREBP translocation is the result of a decrease in glucose metabolism
through an inhibition of the activities of glucose kinase and G6PDH, the rate-limiting en-
zyme of the pentose phosphate pathway [107]. Unlike PPARα and SREBF1, PUFAs regula-
tion of ChREBP and MLX nuclear abundance is less responsive to the type of PUFAs; the
nuclear abundance of ChREBP and MLX depends to a greater extent on the amount of PU-
FAs in cells [108].
2.4.2.4 LXR
Unsaturated FAs antagonize oxysterol binding by LXRα and inhibit LXR action in human
embryonic kidney cells [109]. The hierarchy for this effect is 20:4 ω-6 >18:2 ω-6 >18:1 ω-
9; saturated FAs have no effect [94]. Moreover, it was reported that FAs interfered with
LXRα/RXRβ binding to the LXR responsive element [110]. Of the two LXR subtypes, only
LXRα is sensitive to FA antagonism [111].
2.5 CLA and Obesity
Due to the substantial rise in the prevalence of obesity over the past 30 years, interest in
CLA as a weight loss treatment has increased [112]. The first report that suggested that
CLA may have potential antiobesity effect was published in 1997, when mice were fed a diet
supplemented with 0.5% CLA had a 60% decrease in body fat after 4–5 weeks [113]. Recent
research on CLA shows that body fat accumulation in both humans and animals appears to
be isomer specific, dose responsive and independent of dietary fat content, as well as being
influenced by study duration [47]. Accumulating evidence suggests that the trans-10, cis-
12 CLA isomer appears to be responsible for the reduction of fat pad weight as a result of
its ability to suppress body fat accretion [112]. Supplementation with a CLA mixture (i.e.,
equal concentrations of the trans-10, cis-12 and cis-9, trans-11 isomers) or the trans-10, cis-12
isomer alone decreases body fat mass in many animal studies and some human studies [114].
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This discovery makes this isomer a potential candidate for the treatment and management
of obesity. Several mechanisms have been proposed to explain the CLA-induced reduction
in obesity and fat deposition and these will be discussed.
2.5.1 CLA Regulation of Energy Metabolism
The mechanism by which CLA reduces adiposity in lab animals, and perhaps in humans,
may revolve around pathways that regulate energy balance. Accordingly, potential mecha-
nisms include decreasing energy intake or increasing energy expenditure [112]. A number
of studies have shown that CLA supplementation reduces food/energy intake [114]. The
reduction in food intake can be explained by either the supplement adversely affecting the
palatability of the diet or effects of the absorbed CLA on aspects involved in regulating the
animal’s appetite. In support of the later, CLA supplementation has been shown to to affect
the appetite-regulating genes in the hypothalamus. Indeed, trans-10, cis-12 CLA decreased
the gene expression ratio of proopiomelanocortin to neuropeptide Y and this was associated
with a 24% reduction in food intake in mice [115]. In addition, injection of mixed isomers of
CLA into the hypothalamus of rats resulted in a reduction in the expression of neuropeptide
Y and agouti-related neuropeptides; increases in these two neuropeptide are associated with
a robust increase food intake [116]. However, other reports have shown a large decrease
in body fat mass although there was no alteration in energy intake [114]. This clearly indi-
cates that other mechanisms may be involved in the CLA effects and the reduction in energy
intake is not the only proposed mechanism.
CLA has also been proposed to reduce adiposity by elevating energy expenditure via in-
creasing basal metabolic rate (BMR), thermogenesis or lipid oxidation in animals [112]. A
significant increase in energy expenditure has been observed in mice supplemented with as
low as 0.25% CLA, and the increase in energy expenditure was sufficient to account for the
decreased fat deposition in CLA treated mice [114]. Enhanced thermogenesis may be asso-
ciated with an upregulation of uncoupling proteins (UCP) which facilitate proton transport
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over the inner mitochondrial membrane, thereby causing a loss of energy as heat rather than
traping it as ATP [112]. UCP2 is the most highly expressed UCP in a variety of tissues in-
cluding white adipose tissue (WAT) [112]. In this regard, CLA supplementation in rodents
has been shown to induce UCP2 expression in WAT [117]. CLA also increased the expression
of carnitine palmitoyltransferase 1 (CPT1) in WAT which is involved in mictochondrial FA
uptake and catalyze the rate limiting step of FA oxidation [118].
Other studies have demonstrated increased lean body mass (LBM) in CLA supplemented
mice and this was associated with higher level of energy expenditure when expressed on a
body mass basis [119, 120]. However, the proposed increase in LBM is generally based on
an increase in percent body protein which is confounded by the reduction in body fat oc-
curring in CLA treated mice; when the actual body protein mass is calculated, contrary to
author conclusions no increase in total body protein is observed (eg. calculations of data
from [113, 121, 122]. Nevertheless, the proposed mechanism by which CLA increases LBM
is based on evidence from rodent studies [112]. CLA is thought to increase bone mineral
density by upregulating osteogenic gene expression and by downregulating osteoclast bone
resorbing activity [120]. Alternatively, CLA may suppress the adipogenesis of pluripotent
mesenchymal stem cells in bone marrow and instead enhance their commitment to become
osteoblasts (bone-forming cells). In contrast, cis-9, trans-11 CLA increased adipocyte differ-
entiation and decreased osteoblast differentiation [112]. Consistent with these data, CLA
(isomer mixture) supplementation of rats treated with corticosteroids, which decrease mus-
cle and bone mass, prevented reductions in LBM, bone mineral density, and bone mineral
content [123]. Collectively, these findings provide evidence that one mechanism by which
CLA reduces adiposity may be an increased energy expenditure via increased mitochondrial
uncoupling and FA oxidation in WAT, or via increased muscle or bone mass [112].
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2.5.2 CLA Regulation of Preadipocyte Differentiation
The differentiation of preadipocyte into mature adipocyte is mediated by a series of pro-
grammed changes is gene expression [114]. This is mainly controlled by a cascade of tran-
scription factors particularly CCAAT/enhancer binding protein (C/EBP) and PPAR fami-
lies. C/EBPα and PPARγ are considered to be the master regulators of adipocyte differenti-
ation [112] functioning to coordinate the expression of genes involved in creating and main-
taining the adipocyte phenotype [114]. Trans-10, cis-12 CLA treatment has been reported to
reduce adipogenesis and lipogenesis by attenuating PPARγ, C/EBPα, SREBF1-c, LXRα and
adipocyte-specific FA binding protein expression [112].
2.5.3 CLA Regulation of Lipid Synthesis
The CLA-induced reduction in fat deposition corresponds to decreased lipid accumulation
by adipocytes [114]. Numerous proteins involved in lipogenesis are decreased with CLA
treatment. For example, LPL, ACAC, FASN and SCD are all decreased in the adipose tissue
of mice when the diet is supplemented with mixed CLA isomers or trans-10, cis-12 CLA [112].
The expression of lipogenic genes is regulated by SREBF1-c whose mRNA abundance has
showed a tendency to decrease with CLA feeding. PPARγ, another important transcription
factor in adipogenesis, was also downregulated in mice after supplementation with a CLA
mixture [114]. PPARγ is a major activator of many lipogenic genes, including glycerol-3-
phosphate dehydrogenase, LPL and lipin, as well as genes encoding lipid-droplet-associated
proteins such as perilipin and adipocyte-differentiation-related protein [124]. LPL, a key en-
zyme in lipid metabolism in the adipocyte, hydrolyzes the circulating lipoprotein TG thereby
releasing FAs that can then be taken-up and re-esterified by the adipocytes [114]. In 3T3-
L1 adipocytes, it has been shown that LPL activity decreased in a dose-dependent pattern
by CLA treatment. Moreover, the inhibition of LPL was significantly correlated with the
CLA-induced reduction in lipogenesis [112]. The active CLA isomer appears to be trans-
10, cis-12 because it was shown to decrease TG content of human adipocytes in culture by
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decreasing glucose and FA uptake whereas cis-9, trans-11 CLA had no effect [114]. Addi-
tional support for this hypothesis arises in the observed shifts in glucose transporter type 4
(GLUT-4) protein concentration, a rate-limiting step for glucose uptake in skeletal tissue and
white adipose tissue. A dietary supplement containing 1.0% CLA markedly downregulated
GLUT-4 mRNA levels in white and brown adipose tissues, but upregulated GLUT-4 mRNA
levels in skeletal muscle in mice [114]. The CLA-induced reductions of GLUT-4 mRNA level
and protein concentration in adipose tissue are consistent with a role for CLA inhibition of
the conversion of glucose into fat [114]. On the other hand, rates of lipolysis, the process
by which stored TG are mobilized through the action of hormone sensitive lipase (HSL),
were increased by CLA treatment in WAT thereby providing free FA for uptake in metabol-
ically active tissues (i.e., liver and muscle). In this regard, lipolysis was increased in 3T3-L1
adipocytes or newly differentiated human adipocytes when cell culture were acutely treated
with mixed CLA isomers or trans-10, cis-12 CLA [112]. Moreover, La Rosa et al. [118] ob-
served increased mRNA abundance of HSL in mice following 3 days of trans-10, cis-12 CLA.
2.5.4 CLA Induced Inflammatory Response
The primary function of WAT is energy storage, but this tissue also has the ability to produce
a number of proinflammatory cytokines [112]. These adipokines (i.e., cytokines produced by
adipose tissue) can cause insulin resistance, thereby suppressing lipid synthesis and increas-
ing lipolysis in adipocytes [112]. Induction of these inflammatory genes is dependent on
various cellular kinases, including mitogen activated protein kinases (MAPK), and is driven
by transcription factors such as nuclear factor kappa B (NFκB), which have been reported to
directly antagonize PPARγ [112]. Tumor necrosis factor (TNFα), in particular, exerts potent
antiadipogenic effects [125], and interleukin (IL)-1β and interferon γ have been observed to
induce delipidation of human adipocytes [126]. Treatment with trans-10, cis-12 CLA has also
been shown to increase the expression or secretion of IL-6 and IL-8 from murine [127] and
human [128] adipocyte cultures, as well as TNFα and IL-1β, thereby suppressing PPARγ ac-
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tivity and insulin sensitivity [129]. In human subjects, trans-10, cis-12 CLA supplementation
also increases the levels of inflammatory prostaglandins [130] which has been reported to
inhibit adipogenesis via phosphorylation of PPARγ by MAPKs [131] and via induction of
the normoxic activation of hypoxia-inducible factor-1 [112].
2.6 CLA and Milk Fat Depression
The low-fat milk syndrome, more commonly referred to as milk fat depression (MFD), is
a naturally occurring situation in dairy production when cows are fed highly fermentable
diets or dietary supplements of plant or fish oils [132]. First described over a century ago,
diet-induced MFD can result in a reduction in milk fat yield of up to 50%, and the decrease
involves FAs of all chain lengths. According to the biohydrogenation theory, the basis for
diet-induced MFD relates to an inhibition of mammary lipid synthesis by specific FAs that
are intermediates in the biohydrogenation of dietary PUFAs and are produced only under
certain conditions of rumen fermentation [133]. Trans-10, cis-12 CLA was the first of these
unique intermediates to be identified as a potent inhibitor of milk fat synthesis, and for many
situations of diet-induced MFD, the increase in milk fat content of trans-10, cis-12 CLA is
correlated with the magnitude of the reduction in milk fat yield [133, 134].
CLA are produced as intermediates in the biohydrogenation of linoleic acid by rumen
bacteria. Providing relatively pure CLA isomers to dairy cows by abomasal infusion, to
avoid alterations by rumen bacteria, Baumgard et al. [135] clearly demonstrated that trnas-
10, cis-12 CLA resulted in a reduction in milk fat in dairy cows, and milk fat was rescued
when treatment ceased. On the other hand, in certain situations of diet-induced MFD, the
trans-10, cis-12 CLA content and magnitude of the reduction in milk fat yield do not align
with the dose-response curve generated from abomasal infusion of relatively pure trans-10,
cis-12 CLA. This suggests that in these situations this single CLA isomer does not completely
explain the extent of the decrease in milk fat. Thus, additional inhibitory biohydrogenation
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intermediates have been proposed [133,136], and 2 additional CLA isomers that inhibit milk
fat synthesis (trans-9, cis-11 and trans-10, cis-12) have recently been identified [6]. However,
careful accounting of the rumen production of CLA isomers under different situations of
diet-induced MFD suggests that the isomers identified to date are still not adequate to fully
explain the observed decrease in milk fat yield [137].
Most research investigating CLA effects during lactation has utilized dairy cows, and
results have consistently demonstrated that the inhibitory effects are specific for milk fat;
yields of milk and other milk components are generally unaffected [132]. The reduction in
milk fat secretion reaches a nadir by 4 to 5 d of supplementation and returns to previous
levels in a similar temporal pattern when CLA treatment is terminated [6]. Most studies
have lasted a few days, but long-term studies (20 wk) indicate that the reduction in milk
fat persists throughout the treatment period [138, 139]. Treatment has also encompassed
all phases of the lactation cycle with no adverse effects on animal health and well-being
[138–140]. de Veth et al. [141] combined results from 7 studies and indicated a curvilinear
relation between the increasing dose of trans-10, cis-12 CLA and the reduction in milk fat
production.
The ability of CLA to regulate milk fat synthesis has also been observed in other mammals
including mice, rats, pigs, sheep, goats, and humans [ see review by Bauman et al. [6]]. Most
of these investigations have used dietary supplements containing a mixture of CLA isomers.
However, a study with rats demonstrated that milk fat content and nursing pup growth
were reduced when trans-10, cis-12 CLA was provided as a dietary supplement, whereas cis-
9, trans-11 CLA had no effect [142]. For all species, CLA supplements containing trans-10,
cis-12 have consistently resulted in a reduction in milk fat content, milk fat yield, and/or
growth rate of the nursing neonate.
Phenotypic characterization of CLA-induced MFD provides key insight into the func-
tional mechanism of CLA. Fat is the only milk component inhibited with trans-10, cis-12 CLA
treatment, and the reduction involves FAs of all chain lengths. Thus, mammary effects are
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highly specific for lipid synthesis and include biochemical pathways associated with both de
novo synthesis and the use of preformed FAs [6].
Evaluating the SREBF-regulatory system in bovine mammary epithelial cells (MAC-T cell
line) showed decreased abundance of the nuclear SREBF1 protein during trans-10, cis-12 CLA
inhibition of FA synthesis [143]. SREBF1 is highly expressed in bovine mammary tissue, and
recent investigations demonstrated that mammary expression of SREBF1 and expression of
the genes for proteins involved in the activation and translocation of SREBF were reduced
for both trans-10, cis-12 CLA treatment and diet-induced MFD [9]. Many lipogenic enzymes
have SREBF response elements in their promoter, and, consistent with this, transcription of
mammary genes involved in the complementary pathways for milk fat synthesis was coordi-
nately downregulated during CLA- and diet-induced MFD. Collectively, these observations
are consistent with SREBF1 representing a major signaling mechanism in the regulation of
FA synthesis during CLA-induced MFD [6].
Only a limited number of mechanisms have been investigated in CLA-induced MFD and
these predominantly at the level of gene expression. The coordinated downregulation of li-
pogenic enzymes during MFD is expected to involve multiple regulatory systems and the
interaction of multiple signals. Mechanisms regulating lipid synthesis and SREBF1-c con-
tinue to be identified and will provide strong hypotheses to test the regulation of milk fat
synthesis.
Chapter 3
Ability of Conjugated Linoleic Acid to Reduce
Adiposity is Independent of Spot 14 Gene
Expression
3.1 Introduction
Conjugated linoleic acid (CLA) is a generic term used to describe positional and geometric
isomers of linoleic acid containing two adjacent double bonds. A number of CLA isomers are
naturally produced by rumen bacteria as intermediates in the biohydrogenation of dietary
polyunsaturated fatty acids (PUFA), with cis-9, trans-11 CLA being the predominant isomer
found in ruminant-sourced foods [32]. CLA isomers also originate from industrial hydro-
genation and cis-9, trans-11 and trans-10, cis-12 are the two CLA isomers that have been most
extensively studied [4]. The interest in CLA increased dramatically when in vivo and in vitro
studies documented a wide range of beneficial effects relating to cancer, atherosclerosis, and
obesity [4, 48]. Investigations of the antiobesity effect of CLA have demonstrated a reduc-
tion of body fat occurred in several animal models when CLA was included at ≤ 1% of the
diet [144]. This CLA-mediated delipidation is mainly attributed to the trans-10, cis-12 CLA
isomer and involves, but not limited to, a reduction in de novo lipid synthesis (DLS) [145].
The mechanism by which CLA affects de novo lipid synthesis (DLS) is not fully understood
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but it involves a downregulation of the expression and/or activity of the key lipogenic genes
and transcription factors in the process of DLS.
The thyroid hormone responsive spot 14 (S14) gene encodes for a small nuclear protein
that is predominantly expressed in lipid synthesizing tissues like liver, adipose tissue and the
lactating mammary gland [34]. Rates of lipogenesis and S14 gene expression are highly cor-
related. They are increased by triiodothyronine (T3) injection [37,146,147] and feeding a high
carbohydrate diet [38, 148] and decreased by fasting, feeding diets high in PUFAs [149, 150],
and treatment with glucagon [146] or catecholamines [151]. Although the exact function of
S14 is still unclear, its tissue expression profile [34, 152], nuclear localization [153], rapid ex-
pression relative to other lipogenic genes [154] and impaired lipogenesis and lipogenic gene
expression in primary hepatocytes transfected with S14 antisense oligonucleotide [43], sug-
gest that this protein might be associated with normal lipogenesis. As expected, a mouse
model possessing a targeted disruption in the S14 gene exhibits impaired DLS in the mam-
mary gland [45]. Similarly, treatment of lactating dairy cows with trans-10, cis-12 CLA caused
a reduction in de novo synthesis of milk fatty acids (FAs) accompanied by a significant re-
duction in the mRNA abundance for S14 [9] and growing mice receiving dietary trans-10,
cis-12 CLA had a significant reduction in body fat and reduced S14 gene expression [9, 145].
Based on the S14 partial knockout (S14 null) mice phenotype in mammary gland and the
white adipose tissue (WAT) gene expression of mice treated with CLA, we hypothesized
that the S14 gene might be essential for normal lipogenesis in WAT. Moreover, S14 might
be essential to CLA effect on lipid metabolism. Therefore, we conducted this experiment to
examine these hypotheses.
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3.2 Material and Methods
3.2.1 Animals and Treatments
All experimental procedures were approved by the Cornell University Institutional Animal
Care and Use Committee and mice were maintained in accordance with NIH Guide for the
Care and Use of Laboratory Animals. Mice for the current studies were the progeny of wild
type (Wt) and S14 null C57B1/6J breeding pairs that were kindly provided by Dr. C. Mariash
(University of Minnesota, Minneapolis, MN). The genotype of the progeny was determined
by multiplex PCR according to Zhu et al. [155]. Mice were routinely fed ad lib a pelleted
rodent diet (22% protein, 5% fat; diet #8640, Harlan Teklad, Indianapolis, IN). At 9 wk of age
mice were shifted to a semipurified low fat diet (Table 3.1; Research Diets, New Brunswick,
NJ).
Male Wt and S14 null mice were assigned to one of four treatments in 2 X 2 completely
randomized factorial design (10/group). For 2 wk mice received either water (control) or
40 ul of CLA supplement (ClarinolTM G-80; Lipid Nutrition, Channahon IL) in equal doses
administrated twice daily. The CLA supplement was in the triglycerides (TG) form with
the trans-10, cis-12 and cis-9, trans-11 CLA isomers representing 37% and 38% of the FAs,
respectively. Other FAs in the supplement included 16:0 (4%), 18:0 (2%), 18:1 cis-9 (12%) and
18:2 cis-9, cis-12 (1%). The amount of the CLA supplement given to the animals was chosen
to provide a daily total CLA of approximately 1% of the diet based on pretrial feed intake.
3.2.2 Data and Sample Collection
The body weight (BW) and feed intake of the mice were measured between 10:00 and 11:00
h on days 1, 2 and 14 of the experiment. On day 14 of the experiment, mice were eutha-
nized at 14:00 h by CO2 inhalation followed by cervical dislocation. Liver and WAT depots
(epidydemal (EPF), mesentric (MEF) , subcutaneous (SCF) and retropritoneal (RPF)) were
immediately dissected, blotted dry, weighed and snap frozen in liquid nitrogen; samples
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Table 3.1: Composition of the Experimental
Diet
Variable g/100 g kcal%
Ingredient
Soybean oil 2.37 5.55
Sunflower oil1 1.90 4.44
Casein 18.96 19.72
Corn starch 47.39 49.30
Maltodextrin 9.48 9.86
Sucrose 9.48 9.86
Celluolose 4.74 0.00
L-Cysteine 0.28 0.30
Mineral mix2 0.95 0.00
Vitamin mix3 0.95 0.99
Choline bitartarate 0.19 0.00
Dicalcium phosphate 1.23 0.00
Calcium carbonate 0.52 0.00
Analysis 4
Protein 19.2 23.7
Carbohydrate 67.3 41.4
Fat 4.2 23.6
1 Trisun high oleic sunflower oil
2 Standard salt mix (S100026)
3 Standard vitamin mix (V10001)
4 Analysis calculated based on nutrient content of
individual ingredients. Diet energy content was 3.85
kcal/g.
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were then stored at -80 0C for subsequent RNA and FA analyses.
3.2.3 Sample Analysis
3.2.3.1 FATTY ACID ANALYSIS
FA methyl esters of the CLA supplement were prepared by mild acid methylation using
1% sulfuric acid in methanol according to Christie [156]. Dietary lipids were extracted and
determined by the method of Sukhija and Palmquist [157]. The lipid extraction from liver
and EPF was according to Hara and Radin [158] as modified by Castaneda-Gutierrez et al.
[159]. Methylation of FAs in the lipid extracted from diet and tissues was performed by
base-catalyzed transmethylation according to Christie [160] as modified by Chouinard et al.
[161]. The FA methyl esters were quantified using gas liquid chromatography (GCD system
HP G1800 A; Hewlett Packard, Avondale, PA) equipped with a CP-Sil 88 capillary column
(100 m x 0.25 mm i.d. with 0.2-m film thickness; Varian Instruments, Walnut Creek, CA).
Gas chromatographic conditions for separation of the FA methyl esters were described by
Castaneda-Gutierrez et al. [159]. FA peaks in chromatograms were identified and quantified
using pure methyl ester standards (GLC569 and GLC60, NuChek Prep, Elysian, MN). The
FA profile of the diet is presented in Table 3.2. Oleic acid (45.9%) and linoleic acid (30.0%)
were the major FAs in the semipurified diet fed throughout the experimental period.
3.2.3.2 RNA EXTRACTION AND REAL-TIME PCR
Total RNA was extracted from ∼ 30 mg of liver and ∼ 70 mg of EPF using the RNeasy Lipid
kit (Qiagen, Valencia, CA). Potential genomic DNA contamination was excluded through
on-column DNase treatment (RNase-Free DNase Set; Qiagen). Moreover, RNA concentra-
tion and quality were determined by a 2100 BioAnalyzer (Agilent Technologies, Santa Clara,
CA). Total RNA was reverse transcribed using SuperScript III First Strand Synthesis kit (In-
vitrogen) with random primers. Quantitative real-time PCR (qRT-PCR) assays were devel-
3.2 Material and Methods 39
Table 3.2: Fatty Acid Composition of
the Experimental Diet1
Fatty Acid g/100 g
8:0 0.03
10:0 0.07
12:0 2.25
14:0 4.06
14:1, cis-9 0.01
16:0 7.12
16:1, cis-9 0.11
18:0 3.01
18:1, cis-9 45.93
18:2, cis-9, cis-12 30.01
18:3, cis-9, cis-12, cis-15 2.64
others 4.76
1 Does not include CLA supplement
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oped for genes of interest (Table A.1). Briefly, primers were designed using Primer3Plus [162]
to span the exon boundaries when possible and the optimal primers were selected. qRT-PCR
reaction included Power SYBR R© Green PCR Master Mix (Applied Biosystems, Carlsbad,
CA) and 400 nmol/L of gene-specific forward and reverse primers (Invitrogen, Carlsbad,
CA). Twenty five ng cDNA was amplified using a 2-step program (95◦C for 15 s and 60◦C for
60 s) with an ABI PRISM 7000 sequence detection system (Applied Biosystems). The speci-
ficity of the primers was verified by presence of a single product in the dissociation curve
at the end of amplification process. A standard curve was derived from serial dilutions of
pooled cDNA from adipose or liver tissues. Relative mRNA concentrations were expressed
in arbitrary units and the logarithms (base 10) of concentrations were plotted against the
threshold cycles (CTs). The resulting least square fit was used as the standard curve to de-
rive the arbitrary concentration for each sample.
3.2.3.3 LIVER TRIGLYCERIDE DETERMINATION
Total liver lipid was extracted according to Folch et al. [163]. Briefly ∼ 150 mg liver tissue
was homognized with 3 ml of 2:1 (v/v) chloroform-methanol mixture and vortexed for 40
min. The extract was rinsed by addition of 0.6 ml of water, mixed and vortexed for 40 min
followed by centrifugation for 1 min at 2500 rpm (1430g). An aliquot was removed (∼ 100 ul)
from the bottom phase and used to determine the TG concentration based on the Hantzsch
condensation for estimating serum TG according to Fletcher [164] as modified by Foster
and Dunn [165]. The reference curve was generated using glycerol trioleate (T-7140; Sigma-
Aldrich Co., St. Louis, MO).
3.2.4 Statistical Analysis
Data were analyzed using ANOVA model in R statistical package [166]. The model included
the fixed effect of genotype (Wt and S14 null) and CLA treatment, and the interaction of
genotype and CLA treatment. The interaction term was dropped from the model if it there
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was no statistical or graphical evidence of an interaction. When the interaction effect was
significant, preplanned contrasts were used to test the genotype effect within the control
groups and the CLA effect within each genotype. The animal BW of the first 2 days of treat-
ment were averaged and used as covariate for the statistical analysis of BW, feed intake, and
the weights of liver and different fat depots. The covariate was removed from the model if
P > 0.3. For gene expression analysis, two house keeping genes ((18S ribosomal RNA (18S)
and beta-2-micro-globulin (B2M), Table A.1) were used to normalize gene expression data.
The normalization factor was used as covariate in statistical analysis of the tested genes and
it was removed from the model if the effect was P > 0.3. The normality and variance homo-
geneity assumptions of the model were verified by checking the studentized residual dis-
tribution and the plot of studentized residuals versus predicted values. Log transformation
was performed to meet the model assumption for some response variables (SCF and RPF
depot weights and S14 mRNA level). Data points were considered outliers and excluded if
studentized residuals were > -3 or < 3; this rarely occurred and represented one data point
per response variable.
3.3 Results
3.3.1 Performance Parameters and Adipose Depots
Treatment had little effect on growth; although differences were significant, BW for the two
genotypes and CLA treated groups differed by only 1 to 4% with the overall final average of
24.1 g (SEM = 0.27). Feed intake was approximately 10% lower in the CLA-treated group (P
< 0.0001) and 5% higher (P = 0.02) in the S14 null mice. S14 null mice had about 25% less EPF
than the Wt group (P = 0.01), but other fat depots were similar in weight between the two
groups (Figure 3.1). However, CLA treatment decreased substantially the weight of all fat
depots, and this was especially evident in the EPF, SCF and RPF depots where the reduction
was almost 50% compared to the control mice (P < 0.0001). The MEF depot was the least
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responsive to CLA treatment and it was decreased by less than 20% (P = 0.02). There was no
evidence of CLA by genotype interaction on the weight of different fat depots.
3.3.2 Liver Weight and Liver Triglyceride Content
Treatment effects on liver weight and liver TG content are shown in Figure 3.2. The S14 null
mice had slightly larger livers (∼ 10%) compared to Wt animals (P < 0.001) and CLA treat-
ment increased liver weight (P < 0.001) regardless of the genotype. CLA treatment resulted
in a substantial increase in the hepatic TG content in both S14 null and Wt mice (P < 0.0001).
3.3.3 Tissue Fatty Acid Profile
Treatment effects on the FA profile of EPF and liver are shown in Table 3.3 and Table 3.4,
respectively. The FA profile was relatively similar between the two genotypes for both EPF
and liver, an exception being a reduction in the proportion of palmitic acid in both tissues
for the S14 null mice. In the case of WAT, the proportion of oleate was increased in the
S14 null mice. In CLA supplemented animals, both cis-9, trans-11 and trans-10, cis-12 CLA
isomers were incorporated into EPF and liver lipid (P < 0.0001) with the relative increase
being greater for cis-9, trans-11 CLA in both tissues. In addition, CLA treatment induced
extensive changes in the weight percent for many FAs. In EPF there was a decrease in the
proportion of the myristate, palmitoleate and linoleate, whereas CLA treatment increased the
proportion of oleate and linolenate. CLA significantly increased oleate to stearate (18:1/18:0)
ratio in the EPF from S14 null mice. In liver lipids, CLA treatment resulted in an increase in
the proportion of the myristate, oleate, and linolenate. In contrast, there was a decrease in
proportion of the stearate and linoleate. CLA also significantly increased the hepatic lipid
ratio of oleate to stearate (18:1/18:0) in both genotypes.
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Figure 3.1: Treatment Effect on White Adipose Tissue Deposition. Nine wk-old male
C57BL/6J wild type (Wt) and S14 null (KO) mice were fed a semipurified low fat diet and
received either water (CON) or 40 ul of conjugated linoleic acid (CLA) as oral supplement
daily for 2 wk. At the end of the study, mice were euthanized and different fat depots were
dissected and weighed. Each bar represents the mean ± SE (n = 10). There was a CLA effect
for all depots (P < 0.05), but significant genotype effect only for epidedymal depot (P = 0.01)
and no interaction effect (P > 0.65).
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Figure 3.2: Treatment Effect on Total fat, Liver Weight and Liver Triglyceride Concentra-
tion. Nine wk-old male C57BL/6J wild type (Wt) and S14 null (KO) mice were fed a semipu-
rified low fat diet and received either water (CON) or 40 ul of conjugated linoleic acid (CLA)
as oral supplement daily for 2 wk. At the end of the study, mice were euthanized, liver and
different fat depots were weighed and liver TG concentration was determined. Each bar rep-
resents the mean ± SE (n = 10 for total fat and liver and n = 4 for TG ). There were CLA and
genotype effects for liver weight (P < 0.001), and CLA effect (P < 0.0001), but no genotype
effect (P = 0.68) for liver TG. There was CLA effect (P < 0.0001) but no genotype for total fat
weight.
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Table 3.3: Treatment Effects on Adipose Fatty Acid Profile1
Wt KO P Value
FA (% of total FAs) CON CLA CON CLA Genotype CLA Interaction
14:0 1.10±0.13 0.79±0.12 1.32±0.11 0.98±0.17 0.10 <0.05 0.92
16:0 18.39±0.47 17.91±0.51 16.04±1.00 16.43±0.39 <0.01 0.93 0.36
16:1, c-9 5.97±0.40 3.29±0.19 5.48±0.21 3.41±0.14 0.50 <0.01 0.29
18:0 1.89±0.13 1.84±0.03 1.82±0.18 1.62±0.03 0.13 0.18 0.45
18:1, cis-9 35.69±0.62 41.57±0.89 37.86±0.54 43.74±1.19 0.02 <0.01 1.00
18:2, cis-9, cis-12 25.74±0.40 23.04±1.00 25.11±2.00 21.64±1.82 0.49 0.05 0.80
CLA, cis-9, trans-11 ND2 1.15±0.10 ND 1.09±0.12 0.77 <0.0001 NA3
CLA, trans-10, cis-12 ND 0.54±0.06 ND 0.46±0.04 0.31 <0.0001 NA
18:3 0.68±0.03 0.78±0.02 0.83±0.05 0.99±0.05 < 0.01 <0.05 0.52
20:4 0.16±0.01 0.18±0.01 0.15±0.01 0.17±0.01 0.55 0.15 0.81
22:6 0.17±0.01 0.10±0.01 0.14±0.02 0.08±0.02 0.19 < 0.01 0.89
— — — — — — —
18:1/18:0 19.08±1.06 22.65±0.38 19.34±1.30 27.03±0.97 < 0.05 < 0.01 0.07
1 Nine wk-old male C57BL/6J wild type (Wt) and S14 null (KO) mice were fed a semipurified
low fat and received either water (CON) or 40 ul of conjugated linoleic acid (CLA) as oral
supplement daily for 2 wk. At the end of the study, mice were euthanized, epidydemal WAT
samples were collected and fatty acids were extracted and quantified using gas liquid
chromatography. Values represent observed mean ± SE (n = 4).
2 ND = Not detected (< 0.05 % of total FAs)
3 NA = Not applicable
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Table 3.4: Treatment Effects on Hepatic Fatty Acid Profile1
Wt KO P Value
Fatty acid variable CON CLA CON CLA Genotype CLA Interaction
14:0 0.37±0.06 0.48±0.04 0.43±0.05 0.59±0.08 0.17 0.05 0.70
16:0 24.20±1.05 25.18±0.20 21.56±0.96 22.40±0.51 <0.01 0.26 0.93
16:1, cis-9 3.15±0.20 2.94±0.34 2.69±0.06 2.79±0.47 0.35 0.87 0.62
18:0 8.68±0.43 6.14±0.92 9.53±0.13 7.12±1.2 0.27 <0.01 0.93
18:1, cis-9 23.77±1.77 31.94±2.46 21.18±0.72 30.06±2.99 0.32 <0.01 0.87
18:2, cis-9, cis-12 10.50±1.18 8.54±0.70 12.09±0.24 8.75±0.63 0.26 <0.01 0.38
CLA, trans-10, cis-12 ND2 0.16±0.02 ND 0.14±0.03 0.53 <0.0001 NA3
18:3 0.59±0.05 0.93±0.12 0.60±0.04 0.97±0.12 0.83 <0.01 0.87
20:4 5.01±0.43 3.04±0.57 6.10±0.12 3.67±0.65 0.10 <0.01 0.65
22:6 5.82±0.64 3.68±0.69 6.84±0.06 4.74±0.93 0.14 <0.01 0.98
— — — — — — —
18:1/18:0 2.78±0.84 5.71±0.84 2.23±0.84 4.79±0.84 0.39 <0.01 0.83
1 Nine wk-old male C57BL/6J wild type (Wt) and S14 null (KO) mice were fed a semipurified
low fat and received either water (CON) or 40 ul of conjugated linoleic acid (CLA) as oral
supplement daily for 2 wk. At the end of the study, mice were euthanized, liver samples were
collected and fatty acids were extracted and quantified using gas liquid chromatography.
Values represent observed mean ± SE (n = 4).
2 ND = Not detected (< 0.05 % of total FAs)
3 NA = Not applicable
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3.3.4 Adipose Gene Expression
Treatment effects on mRNA abundance of adipose genes are presented in Figure 3.3. As ex-
pected, S14 mRNA was negligible in the S14 null mice. The mRNA levels of acetyl-coenzyme
A carboxylase alpha (ACACA) (P = 0.08), stearoyl-coenzyme A desaturase 1 (SCD1) (P = 0.04)
and lipoprotein lipase (LPL) (P = 0.07) were upregulated in the S14 null mice compared to
Wt. CLA treatment decreased the S14 mRNA abundance in the Wt mice by almost 75% (P =
0.03). Similarly, CLA treatment downregulated the mRNA abundance of fatty acid synthase
(FASN) (P < 0.01) and ACACA (P = 0.02) by about 60% and sterol regulatory element bind-
ing transcription factor 1-c (SREBF1-c) (P = 0.04) by almost 40% in both genotypes. On the
other hand, CLA significantly decreased the mRNA level of SCD1 in S14 null mice (P = 0.03)
and numerically decreased SCD1 in Wt mice (non-significant). Moreover, CLA treatment
increased the abundance of carnitine palmitoyltransferase 1a (CPT1a) gene regardless of the
genotype (P < 0.0001) and there was no CLA effect on the mRNA level of LPL (P = 0.52).
3.3.5 Liver Gene Expression
Treatment effects on mRNA abundance of hepatic genes are presented in Figure 3.4. The CLA
treatment had no effect on the mRNA abundance of S14 gene in the Wt mice (P = 0.32) or
the mRNA abundance for SREBF1-c (P = 0.84) in either genotype. However, CLA treatment
upregulated the mRNA abundance of FASN (P = 0.02) and SCD1 (P < 0.01) but only for
the S14 null mice. On the other hand, CLA increased the mRNA abundance of peroxisome
proliferator-activated receptor alpha (PPARa) transcription factor in the S14 null mice and
its target gene CPT1a in both genotypes (P < 0.01). Moreover, CLA treatment increased the
expression of fatty acid translocase (CD36) by more than two-fold (P < 0.01) and increased the
mRNA abundance of of fatty acid binding protein 1 (FABP1) (P < 0.01) for both genotypes.
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Figure 3.3: Treatment Effect on Adipose Gene Expression. Nine wk-old male C57BL/6J
wild type (Wt) and S14 null (KO) mice were fed a semipurified low fat diet and received
either water (CON) or 40 ul of conjugated linoleic acid (CLA) as oral supplement daily for
2 wk. At the end of the study, mice were euthanized and epidydemal fat samples were
collected and total RNA was analyzed by RT-PCR for the mRNA abundance of indicated
genes: S14 = thyroid hormone responsive spot 14, SREBF1-c = sterol regulatory element
binding factor 1-c, FASN = fatty acid synthase, ACACA = acetyl-coenzyme A carboxylase
alpha, SCD1 = stearoyl-coenzyme A desaturase, LPL = Lipoprotein lipase, CPT1a = carnitine
palmitoyltransferase 1a. Each bar represents the mean ± SE (n = 7). Significant CLA effect
for all genes except LPL, and genotype effect for ACACA (P = 0.08), SCD1 (P = 0.05) (P = 0.08)
and LPL (P = 0.07).
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Figure 3.4: Treatment Effect on Hepatic Gene Expression. Nine wk-old male C57BL/6J wild
type (Wt) and S14 null (KO) mice were fed a semipurified low fat diet and received either
water (CON) or 40 ul of conjugated linoleic acid (CLA) as oral supplement daily for 2 wk.
At the end of the study, mice were euthanized and liver samples were collected and total
RNA was analyzed by RT-PCR for the mRNA abundance of indicated genes: S14 = thyroid
hormone responsive spot 14, SREBF1-c = sterol regulatory element binding factor 1-c, FASN
= fatty acid synthase, SCD1 = stearoyl-coenzyme A desaturase, PPARa = peroxisome prolif-
erator activated receptor alpha, CPT1a = carnitine palmitoyltransferase 1a, CD36 = fatty acid
translocase, FABP1 = fatty acid binding protein 1. Each bar represents the mean ± SE (n = 7).
Significant CLA effect for FASN, SCD1 and PPARa in S14 null mice (P < 0.05) and for CPT1a,
CD36 and FABP1 in both genotypes (P < 0.01). There was no genotype effect for any gene.
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3.4 Discussion
Due to the substantial rise in the prevalence of obesity over the past 30 years, interest in CLA
as a weight loss treatment has increased [112,167]. The first report that suggested a potential
CLA antiobesity effect was published in 1997, when mice were fed a diet supplemented
with 0.5% CLA had a 60% decrease in body fat after 4–5 wk [113]. Supplementation with
a CLA mixture (equal concentrations of the trans-10, cis-12 and cis-9, trans-11 isomers) or
the trans-10, cis-12 CLA isomer alone decreased body fat mass in many species and several
mechanisms have been proposed to explain the CLA-induced reduction in fat deposition
[51,114]. One of these mechanisms involves decreased lipid accumulation of adipocytes and
downregulation in the expression of enzymes involved in lipogenesis. For example, ACACA,
FASN and SCD1 are all decreased in the WAT of mice when the diet is supplemented with
mixed CLA isomers or trans-10, cis-12 CLA [118, 168–170].
As discussed in the introduction, several lines of evidence suggest that S14 protein may
be involved in the regulation of lipogenesis. Moreover, reports have shown that S14 gene
has been linked to the development or maintenance of obesity in humans; a 48-h fast results
in minimal downregulation of S14 mRNA in WAT of obese patients as compared with non-
obese patients [171]. The objective of the current study was to examine lipogenesis in S14 null
mice and to determine the effect of knocking out the S14 gene on the antiobesity mechanism
of CLA. To address our objective, S14 null and Wt mice were fed a semipurified low fat diet
(4% fat w/w) and treated with CLA for 14 days in a 2 X 2 randomized factorial design. We
observed that knocking out the S14 gene reduced the EPF by 25% (P = 0.01) and the SCF by
13% (P = 0.15) with the total fat mass being reduced by almost 8% compared to the Wt mice.
A similar phenotype has been reported previously where deletion of the S14 gene decreased
fat mass by almost 45% in 29-wk-old male mice [172]. The young age of the mice used in the
present study (11 vs 29 wk of age), the relatively short term observation period (2 vs 29 wk),
and the method used to determine the degree of fatness ( manual dissection vs DEXA scan)
may be the basis for the less dramatic reduction observed in the present study. Nevertheless,
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results suggest that that S14 does play a role in fat deposition.
The role of S14 in fat deposition was further investigated by examining the mRNA abun-
dance of key lipogenic enzymes in WAT of S14 null mice. In contrast to the observed reduc-
tion in fat deposition, SREBF1-c and FASN mRNA abundance were not reduced in the WAT
from the S14 null mice. Interestingly, ACACA and SCD1 mRNA levels were significantly
increased in the epidedymal WAT of the S14 null mice. Although unexpected, Zhu et al. [45]
observed a similar paradox in the milk fat synthesis of S14 null mice. They reported that
TG levels in the milk and mammary tissue were reduced by 28% and the rate of mammary
DLS was decreased by 62% in S14 null mice when compared with Wt. Nevertheless, the S14
null mutation had no effect on mRNA abundance of FASN and ACACA [45]. Moreover, they
reported that ACACA enzyme activity was significantly increased in the lactating mammary
gland of the S14 null mice [45]. Based on these findings, Zhu et al. [45] suggested that the
regulatory effect of S14 on lipogenesis does not involve alteration of the transcription of the
rate-limiting lipogenic enzymes in the mammary gland; we conclude the same for WAT in
the present study. Indeed, malonyl-CoA, the substrate of the FASN reaction, has been shown
to be increased in the mammary gland of the S14 null mice; this suggests that the defect in
lipogenesis may be related to an in vivo reduction in FASN activity and that the S14 protein
may act as an allosteric regulator of FASN in vivo activity [8].
In the present study, knocking out the S14 gene resulted in a modest (10%) increase in
liver weight (P < 0.001) whereas hepatic TG concentration was unchanged. This suggests
that S14 protein may be not required for hepatic lipogenesis under the current experiment
conditions. Zhu et al. [155] reached a similar conclusion based on their studies showing that
knocking out the S14 gene did not affect hepatic lipogenesis when the mice were acutely (24
h) treated with T3, fed a high carbohydrate diet, or administrated T3 plus fed a high carbo-
hydrate diet [155]. Hepatic mRNA levels of several lipogenic genes including FASN were not
different between the Wt and S14 null mice 24 h after being given T3 [155]. Likewise, in the
present study there were no differences in the hepatic mRNA abundance of SREBF1-c, FASN
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or SCD1 between the S14 null and Wt mice. One explanation for the failure of the S14 null
mice to have a reduction in hepatic lipogenesis is that another related protein might compen-
sate for the lack of S14 [8]. Indeed, a paralog of S14 has been identified and given the name
S14 related protein (MIG12) [45]. The MIG12 gene has many similarities to the S14 gene; it
is well expressed in lipogenic tissues (liver and adipose tissue), and it is regulated in liver
by carbohydrate feeding in vivo, and by glucose metabolism in cultured hepatocytes [173].
Furthermore, just as for S14, a carbohydrate response element (ChRE) was detected in the
MIG12 promoter where the hetero-dimer of carbohydrate response element binding protein
(ChREBP) and MAX-like protein X (MLX) bind [173]. These similarities raises the possibil-
ity that MIG12 functions similarly to S14 in such tissues [173] and may compensate for the
absence of S14 in the S14 null mouse. Moreover, MIG12 is highly expressed in WAT com-
pared to liver and mammary tissue (almost 5-fold greater when compared with liver) [45].
Moreover, in S14 null mice, the MIG12 mRNA abundance is greater than that in the Wt mice
(although non significant) [45]. Therefore, the increased expression of the MIG12 in the null
mice might explain the greater expression of both ACACA and SCD1 in the S14 null mice
compared to the Wt. Interestingly, MIG12 was less abundant in mammary gland compared
with liver which may explain the contrast in the lipogenic phenotype between the two tissues
in the S14 null animal [45]. Using small interfering RNA to simultaneously reduce levels of
S14 and MIG12 in cultured primary hepatocytes, the rates of lipogenesis were decreased by
approximately 65% in cells treated with insulin and high glucose. Furthermore, expression
of either S14 or MIG12 gene products was sufficient to fully restore normal lipogenesis [36].
In the present study, there was no genotype effect on the live BW, and this is in agreement
with the findings of Anderson et al. [172]. They reported that first generation backcross (N1)
S14 null and Wt mice born to homozygous dams and maintained on a 4% fat diet from the
time of weaning showed no significant differences in BW at 8 wk of age. Moreover, N11
backcross S14 null mice fed the 4% fat diet was not different in BW compared to Wt mice at
31 wk of age.
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Dietary supplementation with CLA significantly reduced EPF, SCF and RPF depots by
almost 50% in both Wt and S14 null mice with no evidence of a CLA by genotype interaction.
The total dissected fat tissue, which include the MEF depot, was decreased by almost 40% in
the CLA supplemented group. Similar effects of CLA on fat deposition have been reported
previously in mice and other animal models [114]. The CLA supplement used in the current
study was a mixture of the cis-9, trans-11 and trans-10, cis-12 isomers of CLA. The trans-
10, cis-12 CLA isomer was first shown to inhibit milk fat synthesis in dairy cows [135] and
subsequent studies have verified that the trans-10, cis-12 CLA was the specific CLA isomer
responsible for the delipidative effects in growing animals [168, 174, 175]. As low as 0.1% of
the diet as trans-10, cis-12 CLA was able to decrease the gonadal fat pad [176] and 0.2% trans-
10, cis-12 CLA decreased significantly both RPF and EPF depots when given for 4 wk [177].
In the current study, the fact that CLA-induced a delipidative effect regardless of the
genotype indicates that expression of the S14 gene is not essential for the CLA mechanism.
The mechanistic details of CLA on adiposity are not yet fully understood but CLA treatment
has been shown to decrease the mRNA abundance and/or the activity of lipogenic enzymes
in WAT [118, 168–170, 178]. In the current study, the mRNA abundance of SREBF1-c, FASN
and ACACA decreased by almost 30% - 70% regardless of the genotype. However, DLS is
relatively less important in fat deposition when fat is provided in the diet. In this case the
dietary supply of preformed FAs would be the major source of FAs for body fat accretion.
CLA reduces body fat even in situations where animals have been fed a high fat diet, so
the mechanism must involve more than just effects on DLS synthesis. Indeed, results from
various studies have suggested that in addition to DLS, CLA effects can involve reduction
of energy intake, increase in energy expenditure, inhibition of adipogenesis, induction of
inflammation, stimulation of lipolysis and induction of apoptosis [112]. However, most in-
vestigations have utilized trans-10, cis-12 CLA doses of 0.5% of diet or greater and a recent
study demonstrates this may complicate evaluation of mechanism. Foote et al. [176] showed
that a CLA dose of 0.5% trans-10, cis-12 isomer substantially reduced mammary and gonadal
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fat pads in growing mice and this was associated with an increase in the expression of the in-
flammatory markers; mRNA abundance of chemokine monocyte chemoattractant protein-1,
tumor necrosis factor alpha, interleukin 6 and others were increased by 3- to 6-fold [176]. The
implication was that inflammatory markers were a component of the mechanism whereby
CLA induced a reduction in body fat. However, when Foote et al. [176] used lower doses of
trans-10, cis-12 CLA effects on mammary and gonadal fat were still observed but there were
no effects on inflammatory factors; they concluded these latter effects were a consequence of
an excessive dose of CLA and not essential components of the CLA mechanism for reducing
fat accretion.
In conclusion, while a modest reduction in fat accretion occurred in S14 null mice, there
was no corresponding reduction in the expression of key lipogenic enzymes. Although a
similar phenotype has been reported in mammary gland of S14 null mice [45], this suggests ,
in contrary to our hypothesis, that the regulation of lipogenesis by S14 protein might not take
place through the transcriptional regulation of lipogenic enzymes. A compensatory mecha-
nism in response to decreased lipogenesis might be involved to maintain or upregulate the
lipogenic gene expression. However, the decrease in fat accretion and in mammary lipogene-
sis in the S14 null mice might indicate other roles by which S14 protein regulates lipogenesis
that are not likely to be compensated by other mechanisms in mammary and adipose tis-
sues. Indeed, recent data has confirmed the ability of S14 to form hetero-dimers with other
proteins in the cytoplasm including MIG12 which regulate the activity of ACACA [179].
Moreover, in the mammary gland of S14 null mice, there was an indication of reduction in
the activity of FASN [45]. Altogether these data confirm that S14 might play different roles
in the regulation of lipogenesis and more research is required to explore this possibility. On
the other hand, and in contrary to our hypothesis, S14 protein does not seem to be a compo-
nent in the mechanism of the CLA delipidative effect; in the present study a reduction in fat
accretion by CLA was clearly evident whether the genotype was Wt or S14 null.
Chapter 4
Effect of Fish Oil Supplementation on Mammary
Lipogenesis in Lactating Mice
4.1 Introduction
The long chain ω-3 polyunsaturated fatty acids (LC ω-3 PUFAs), eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), are prevalent in marine fish oil (FO) and represent a
unique class of fatty acids (FAs) that show a wide range of functions in biological sys-
tems. These effects include the ability to modulate gene expression [52], inflammatory pro-
cesses [53] and cellular membrane structure and function as well as signaling pathways in-
volved in normal and pathological cell functions [54]. Recent epidemiological and clinical
studies with humans and biomedical studies using animal models indicate that FO may be
useful for reducing the risk of coronary heart disease and atherosclerosis [180], treating in-
flammatory conditions [181], and preventing certain types of cancer [5].
The ability of LC ω-3 PUFAs to affect lipid metabolism in liver and to a lesser extent
adipose tissue, has been of a considerable interest. Studies involving oral administration of
FO or purified ethyl esters of EPA and DHA in both experimental animals and humans report
a decrease in serum and hepatic levels of triglycerides (TG), cholesterol and phospholipid
[10, 182–187], and a reduction in body fat deposition [11, 62]. Although mechanistic details
are not fully understood, the effects of LC ω-3 PUFAs in liver involve the regulation of the
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activity of metabolic nuclear receptors which results in repartitioning of metabolic fuel (i.e,
FAs) away from TG synthesis and storage toward oxidation, thereby decreasing the substrate
available for very low density lipoprotein synthesis and secretion [63, 182–184].
The effect of LC ω-3 PUFAs on the biology of mammary gland, the major lipid synthe-
sizing organ during lactation, has not been investigated extensively and to the best of our
knowledge the effects on mammary enzymes involved in lipogenesis per se have not been
reported. Mammary lipogenesis is nutritionally regulated and highly responsive to dietary
FA composition [188]. It is also regulated by bioactive FAs. For example, dietary supple-
ments of trans-10, cis-12 conjugated linoleic acid (CLA) were able to induce milk fat depres-
sion (MFD) in lactating ruminants and non-ruminants [6]. Although the mechanisms are
not completely elucidated, the CLA-induced MFD involves a coordinated downregulation
of mammary lipid synthesis characterized by a decrease in de novo FA synthesis and a cor-
responding downregulation in the expression of lipogenic enzymes [6].
Investigations of the effect of FO or LC ω-3 PUFAs on the milk FA composition in lac-
tating mice indicate a trend toward an increase in the proportion of medium chain fatty
acids (MCFAs) in milk fat relative to the control diets [64–68]. Most diets are devoid of MC-
FAs so their presence in milk fat is generally indicative of mammary de novo lipogenesis
(DNL). However, some fish oils do contain modest amounts of MCFAs, especially myristic
acid. Nevertheless, results from the above investigations provide no evidence that the rate
of mammary de novo FA synthesis is reduced by feeding FO or ω-3 PUFAs. However, these
experiments were not designed specifically to address effects on de novo lipid synthesis and
such an effect would be contrary to the well established ability of ω-3 PUFAs to downreg-
ulate hepatic lipid synthesis. Therefore, the objective of the present study was to examine
the effects of FO supplementation on mammary lipogenesis as well as the expression of li-
pogenic genes and transcription factors in mammary and hepatic tissues of lactating mice.
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4.2 Material and Methods
4.2.1 Animals
All experimental procedures related to animals were approved by Cornell University Institu-
tional Animal Care and Use Committee. Eight wk old C57BL/6J mice were purchased from
Jackson Laboratory (Bar Harbor, MA) and housed in group cages under controlled temper-
ature (22-26 0C) and a 12 h light-dark cycle. Mice were fed ad lib a pelleted rodent chow
diet containing 5% fat and 22% protein (diet #8640; Harlan Teklad; Harlan Teklad, IN). At
wk 10 of age, breeding was initiated (1 male/4 females) and once gestation was confirmed
females were housed individually until the end of the study. On d 3 of lactation, litter size
was adjusted to 7 pups per dam through cross fostering.
4.2.2 Design
One wk before parturition, mice were shifted to a semipurified pelleted diet containing 5%
oil. Then on d 6 of lactation, two groups of the dams were randomly switched to semipu-
rified pelleted diets containing 10% oil that were enriched with either oleic acid (high fat
control (HFC)) or FO (n = 8). To account for the effect of dietary oil level, a third group of
mice continued on the semipurified diet containing 5% oil (low fat control (LFC)). The ex-
perimental diets were based on a widely used nutritionally balanced rodent diet (AIN-76A)
and were mixed to our specifications by Research Diets Inc.(New Brunswick, NJ) (Table 4.1).
Dietary oil sources and proportions were chosen so that the HFC diet serves as a control for
FO diet at the high oil level (10%) while the LFC diet accounts for effect of dietary oil level in
comparison with the FO diet. Safflower oil (high oleic acid) and palm oil were provided by
Research Diets Inc. and the menhaden oil (Virginia Prime GoldTM) was provided by Omega
Protein Corp. (Houston, TX).
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Table 4.1: Experimental Diet Composition
Diet1
Variable LFC HFC FO
Ingredient g/100 g
Oil 5 10 10
Safflower oil 2 0.5 4.0 1.0
Menhaden oil 2 - - 9.0
Palm oil 2 4.5 6.0 -
Casein 20.0 21.2 21.2
DL-Methionine 0.3 0.3 0.3
Corn starch 10.0 10.6 10.6
Maltodextrin 5.0 5.3 5.3
Sucrose 50.0 42.4 42.4
Celluolose 5.0 5.3 5.3
Mineral mix 3 3.5 3.7 3.7
Vitamin mix 4 1.0 1.1 1.1
Choline bitartarate 0.2 0.2 0.2
Analysis 5
Protein 20 22 22
Carbohydrate 66 59 59
Fat 5 10 10
1 Diet abbreviations were as follows: LFC, low fat control;
HFC, high fat control; FO, fish oil.
2 The safflower oil contained 78% oleic acid; menhaden oil
contained 12.7% EPA and 12.3% DHA and palm oil
contained 38% palmitic acid and 42% oleic acid.
3 Standard salt mix (S10001).
4 Standard vitamin mix (V10001).
5 Calculated analysis based on individual ingredients. Diet
energy value (kcal/g) were 3.9, 4.1, and 4.1 for LFC,
HFC, and FO, respectively
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4.2.3 Data and Sample Collection
Dams, pups, and feed were weighed daily between 0930 and 1030 h. After 7 d on the experi-
mental diets, pups were euthanized by CO2 at 1130 h and stomach milk clots were collected
and pooled for each litter, and stored at -200C for subsequent analysis. Dams were anes-
thetized with ketamine-zylazine (1 and 0.1 mg/10 g body weight (BW), respectively) and
then euthanized by cervical dislocation while under anesthesia. One #4 mammary gland was
placed in ice-cold isotonic tris-sucrose buffer (0.25 M sucrose, 30 mM Tris, 1m M glutathione
and 1 mM EDTA; pH 7.3) and immediately used to determine lipogenic capacity. The other
#4 mammary gland in addition to liver and fat depots (gonadal , mesentric and perirenal)
were rapidly dissected, weighed, and snap frozen in liquid nitrogen and then stored at -80
0C until further analysis.
4.2.4 Sample Analysis.
4.2.4.1 MAMMARY LIPOGENIC CAPACITY ASSAY
The incorporation of 14C glucose by mammary tissue explants was determined according
to Bauman et al. [189]. Briefly, mammary tissue explants were prepared using a Stadie-
Riggs hand microtome, and ∼150 mg tissue explants were incubated in triplicate in 3 mL
of a modified Krebs-Ringer bicarbonate buffer solution (pH 7.4) that also contained 25 mM
glucose, 0.5 µCi/ml glucose (D-[14C(U)]; PerkinElmer,Waltham, MA) and 0.1 unit insulin.
Vials were gassed with a mixture of O2:CO2 (95:5), sealed, and incubated for 3 h at 37◦ C in a
shaking water bath. After the incubation was terminated, tissue was rinsed, saponified, and
lipids obtained by petroleum ether extraction [190]. One mL aliquots of the petroleum ether
extract together with 10 ml of scintillation fluid (5 g 2,5-diphenyloxazolc per liter toluene)
were assayed for radioactivity in a Packard Tri-Carb 2200CA Liquid Scintillation Counter.
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4.2.4.2 FAT AND FA PROFILE
Milk clot samples were freeze dried overnight, thoroughly mixed and ∼20 mg were ana-
lyzed for fat concentration and FA profile according to Harvatine [191]. Briefly, internal
standards (triheptadecanoin [C17:0 methyl ester] and trinonadecanoin [C19:0 methyl ester]
were added and the milk clot fat was extracted according to Hara and Radin [158]. The fat
was methylated overnight at 400C in 1% methanolic sulfuric acid and subsequently trans-
methylated [191]. The methyl esters were then quantified by gas chromatography using a
fused-silica capillary column (CP-Sil 88; 100 m x 0.25 mm (i.d.); Varian Inc., Santa Clara, CA)
and conditions as described by Perfield et al. [192]. FA peaks on the chromatograms were
identified and quantified using pure methyl ester standards (GLC569, GLC60; NuChek Prep,
Elysian. MN). A butter reference standard (CBM 164; Commission of the European Commu-
nity Bureau of References, Brussels, Belgium) was used to validate recoveries and correction
factors for individual FA. Milk clot fat concentration was determined based on dilution of
the internal standards.
Dietary FAs were extracted according to Hara and Radin [158]. Methylation and gas
chromatography analysis was as described for milk clot samples. The FA composition of the
diets is presented in Table 4.2 with each diet having a distinct profile related to the oil source
used in the diet formulation.
4.2.4.3 RNA EXTRACTION AND REAL-TIME PCR
Total RNA was extracted from ∼30 mg of mammary tissue or liver using RNeasy Lipid kit
(Qiagen, Valencia, CA). The potential genomic DNA co-extraction with RNA was excluded
through on-column DNase treatment (RNase-Free DNase Set; Qiagen). RNA concentration
and quality were determined by 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA)
and samples with RNA Integrity Number (RIN) less than 8 were excluded from downstream
reactions. Total RNA was reverse transcribed using High Capacity cDNA Reverse Transcrip-
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Table 4.2: Dietary Fatty Acid Profile
Diet1
Fatty acids2 LFC HFC FO
g/100 g
12:0 0.25 0.18 0.35
14:0 3.45 2.85 10.28
16:0 38.13 32.31 19.73
16:1, ω-7 0.44 0.43 11.69
18:0 5.30 4.71 4.60
18:1, ω-9 35.64 45.05 10.88
18:1, ω-7 0.79 0.76 2.76
18:2, ω-6 13.94 11.76 8.88
18:3, ω-3 0.52 0.53 1.59
20:4, ω-6 - - 1.08
20:4, ω-3 - - 1.28
20:5, ω-3 , EPA - - 10.86
22:5, ω-3 - - 1.92
22:6, ω-3, DHA - - 5.93
Others 1.50 1.42 8.09
1 Female C57BL/6J mice received either
semipurified, low fat control diet containing
0.5% safflower oil and 4.5% palm oil (LFC); high
fat control oleic acid enriched diet containing 4%
safflower oil and 6% palm oil (HFC); or fish oil
enriched diet containing 1% safflower oil and
9% menhaden oil (FO). Diets were fed from d 6
to d 13 of lactation (n = 8).
2 FA profile of the complete diet which included
the supplemented oils.
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tion kit (Applied Biosystems, Carlsbad, CA) with random primers. Quantitative real-time
PCR (qRT-PCR) assays were developed for genes of interest (Table A.1). Briefly, primers were
designed using Primer3Plus [162] to span the exon boundaries when possible and the opti-
mal primers were selected. Quantitative real-time PCR (qRT-PCR) reaction included Power
SYBR R© Green PCR Master Mix (Applied Biosystems) and 400 nmol/L of gene-specific for-
ward and reverse primers (Invitrogen, Carlsbad, CA). Twenty five ng cDNA was amplified
using a 2-step program (95◦C for 15 s and 60◦C for 60 s) with an ABI PRISM 7000 sequence
detection system (Applied Biosystems). The specificity of each primer was verified by the
presence of a single product in the dissociation curve at the end of amplification process. A
standard curve was derived from serial dilutions of pooled cDNA from mammary or liver
tissues. Relative concentrations were expressed in arbitrary units and the logarithms (base
10) of concentrations were plotted against crossing points. The resulting least square fit was
used as the standard curve to derive the arbitrary concentration for each sample.
4.2.5 Statistical Analysis.
Data were analyzed using ANOVA model in R statistical package [166]. The average of
d 5 and d 6 data was used as co-variant in the analysis of dam feed intake and BW gain.
A normalization factor [193] was generated from three house keeping gene (18S, B2M and
ribosomal protein S20 (RPS20)) and used as co-variate in the analysis of gene expression
data. Co-variates were removed from the model when P > 0.3. Data points with studentized
residuals outside the range of 2.5 to -2.5 were considered outliers and excluded from analysis.
Few points were excluded in analysis and rarely more than one per response variable.
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4.3 Results
4.3.1 Performance-Related Variables
The effect of dietary treatment on performance parameters of the experimental animals is
shown in Table 4.3. Feed intake was similar for dams receiving the LFC and HFC diets, but
the FO supplemented group had a lower total (P < 0.001) and average daily (P = 0.01) feed
intake. There were no significant treatment effects on lactating dam BW at the end of the
study (P = 0.26) or on BW gain (P = 0.22). Similarly, there were no significant treatment
effects on litter growth parameters in terms of final litter weight (P = 0.70) or weight gain (P
= 0.59) during the 7-d experimental period.
4.3.2 Fat Deposition
In general, the three adipose tissue depots that were quantified followed a similar pattern
for treatment effects. Weights for the gonadal, mesentric and perirenal fat depots were low-
est in the LFC group, intermediate for the HFC group and highest for the FO group (Table
4.3). Combining these depots, the dissected fat mass was 32% and 14% greater for the FO
treatment as compared to the LFC and HFC, respectively.
4.3.3 Milk Clot FA Composition
Treatment effects on milk clot FA profile are shown in Table 4.4. In the present study there
was a distinct treatment effect on the milk fat concentration of FAs that reflected the unique
FA profile for each diet (Table 4.2). Milk fat from the HFC group had an elevated oleic acid
content consistent with that diet having a greater oleic acid content. Likewise, EPA and DHA
were found almost exclusively in the milk fat from the FO group (P < 0.001), and this was
accompanied by higher levels of palmitoleic acid (P < 0.001) and lower oleic acid (P < 0.001)
compared with the other groups.
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Table 4.3: Treatment Effect on Dam Parameters and Litter Weight
Treatment1
Variable LFC HFC FO P Value
Weight Final (g) 27.0±0.5 28.0±0.4 27.8±0.4 0.26
Gain2 (g) 0.6±0.5 1.8±0.5 1.4±0.5 0.22
Feed Intake Total (g) 63.0±1.7a 60.0±1.6a 51.0±1.7b <0.001
Daily (g) 8.9±0.2a 8.6±0.2ab 7.7±0.3b 0.01
Liver Weight (g) 2.36±0.08a 2.20±0.07a 1.79±0.07b <0.001
Lipid (mg/g) 38.0±2.2a 34.1±2.6a 18.3±1.06b <0.001
Fat depot Gonadal (g) 0.24±0.02b 0.29±0.02ab 0.34±0.02a 0.01
Mesentric (g) 0.39±0.03b 0.42±0.02ab 0.47±0.03a 0.12
Perirenal (g) 0.05±0.01b 0.07±0.01a 0.08±0.01a 0.02
Litter Final weight (g) 39.3±0.6 39.6±0.6 38.9±0.6 0.70
Weight gain2 (g) 19.7±0.6 19.9±0.6 19.1±0.6 0.59
1 Female C57BL/6J mice received either semipurified, low fat control diet containing 0.5%
safflower oil and 4.5% palm oil (LFC); high fat control oleic acid enriched diet containing 4%
safflower oil and 6% palm oil (HFC); or fish oil enriched diet containing 1% safflower oil
and 9% menhaden oil (FO). Diets were fed from d 6 to d 13 of lactation (n = 8). On d 13,
dams and their litter were weighed and then euthanized where liver and different fat depots
were dissected and weighed. Values represent LS mean ± SE.
2 Dams’ and litters’ weight gain represent the difference between d 6 and d 13 weight records.
ab
Values with different letters differ statistically with P values as indicated.
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Of particular interest was the effect of treatment on de novo synthesized fatty acids (DS-
FAs). Comparisons of these FAs indicate there were no treatment effects on proportion of
short and medium chain FA (<C16; P = 0.21), although the concentration of C:14 and C:14.1
was slightly lower in milk fat from the HFC treatment group. Moreover, the HFC treatment
had a higher proportion of preformed FAs (> C16) compared with both LFC and FO treat-
ment (P = 0.04).
4.3.4 Mammary Lipogenic Capacity and Gene Expression
Mammary tissue lipogenic capacity was determined by measuring the incorporation of radio-
labeled glucose into lipids. Observed rates were similar to those reported previously for
lactating rodents [190]. Of special interest, we found no dietary treatment effects on the
lipogenic capacity of the mammary explants (Figure 4.1).
Treatment effects on mammary lipogenic gene expression are presented in Table 4.5.
There was no significant treatment effect on mRNA abundance for acetyl-coenzyme A car-
boxylase alpha (ACACA), fatty acid synthase (FASN) and lipoprotein lipase (LPL), key en-
zymes in milk fat synthesis. Likewise, there was no effect of dietary treatment on mRNA
abundance for transcription signaling genes associated with the regulation of lipid synthesis
including the sterol regulatory element binding transcription factor 1-c (SREBF1-c), thyroid
hormone responsive spot 14 (S14), insulin induced gene 1 (INSIG1), insulin induced gene 2
(INSIG2), SREBF chaperone (SCAP) or membrane-bound transcription factor peptidase, site
1 (MBTPS1) (Table 4.5). However, the FO diet did result in a significant reduction in mam-
mary mRNA abundance for stearoyl-coenzyme A desaturase 1 (SCD1) and diacylglycerol
O-acyltransferase 1 (DGAT1).
4.3.5 Liver Weight and Hepatic Gene Expression
The FO treatment resulted in dams with livers that were smaller and contained less fat. Liver
weights for dams on the FO treatment were 19 to 24% lower compared with LFC and HFC
4.3 Results 66
Table 4.4: Treatment Effect on Milk Clot FA Profile
Treatment1
LFC HFC FO P Value
FA (%)2
10:0 2.51±0.21 2.69±0.29 3.00±0.29 0.50
12:0 10.66±0.37 10.01±0.34 9.69±0.34 0.17
14:0 15.85±0.49a 14.03±0.64b 15.90±0.46a 0.02
14:1 0.17±0.01a 0.13±0.01b 0.18±0.01a <0.01
16:1, ω-7 2.44±0.11b 1.64±0.10c 4.97±0.10a <0.001
18:0 2.29±0.05 2.18±0.05 2.14±0.05 0.96
18:1, ω-9 22.91±0.91b 28.62±0.77a 12.77±0.77c <0.001
18:2, ω-6 2.79±0.15c 3.40±0.14b 4.30±0.15a <0.001
20:5, ω-3, EPA 0.07±0.11b 0.09±0.10b 3.08±0.11a <0.001
22:6, ω-3, DHA 0.04±0.01b 0.06±0.01b 3.34±0.21a <0.001
Total by source (%)3
<16 carbons 29.20±1.00 26.86±0.94 28.77±0.94 0.21
16:0 29.41±0.54a 26.71±0.50b 25.96±0.56b <0.01
>16 carbons 37.33±1.39b 42.16±1.19a 38.47±1.19b 0.06
1 Female C57BL/6J mice received either semipurified, low fat control diet containing
0.5% safflower oil and 4.5% palm oil (LFC); high fat control oleic acid enriched diet
containing 4% safflower oil and 6% palm oil (HFC); or fish oil enriched diet
containing 1% safflower oil and 9% menhaden oil (FO). Diets were fed from d 6 to
d 13 of lactation (n = 8). On d 13, pups were euthanized and stomach milk clots
were collected and pooled for each litter.
2 Calculated as % of total FA. Values represent LS means ± SE.
3 FA <16 carbons originate from de novo synthesis, FA >16 carbons originate from
extraction from plasma, and 16 carbon FA originate from both extraction from
plasma and de novo synthesis.
ab
Values with different letters differ statistically at the indicated P values.
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Figure 4.1: Treatment Effect on 14C Glucose Incorporation Rate by Mammary Explants.
Female C57BL/6J mice received either semipurified, low fat control diet containing 0.5%
safflower oil and 4.5% palm oil (LFC); high fat control oleic acid enriched diet containing
4% safflower oil and 6% palm oil (HFC); or fish oil enriched diet containing 1% safflower oil
and 9% menhaden oil (FO). Diets were fed from d 6 to d 13 of lactation (n = 8). Mammary
tissue explants were prepared and ∼150 mg tissue explants were incubated in triplicate in 3
mL of a modified Krebs-Ringer bicarbonate buffer solution (pH 7.4) that also contained 25
mM glucose, 0.5 µCi/ml 14C glucose and 0.1 unit insulin. Vials were gassed with a mixture
of O2:CO2 (95:5), sealed, and incubated for 3 h at 37 ◦C in a shaking water bath. Each bar
represents the mean ± SE (n = 8) expressed as µmole of glucose incroporated into lipids per
100 mg tissue.hr.
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Table 4.5: Treatment Effect on mRNA Abundance of Mammary Genes1
Treatment
LFC HFC FO P Value
Lipid Synthesis ACACA 1.00±0.24 1.03±0.21 0.81±0.20 0.53
FASN 1.00±0.34 1.15±0.35 0.65±0.22 0.25
DGAT1 1.00±0.07a 0.71±0.06b 0.65±0.06b <0.001
LPL 1.00±0.13 1.20±0.14 0.98±0.21 0.54
SCD1 1.00±0.09a 0.81±0.08a 0.49±0.07b <0.001
S14 1.00±0.19 1.13±0.21 0.97±0.19 0.70
SREBF related SREBF1-c 1.00±0.28 0.96±0.28 0.71±0.24 0.55
SCAP 1.00±0.19 1.06±0.19 1.19±0.21 0.59
INSIG1 1.00±0.21 1.04±0.22 0.93±0.21 0.87
INSIG2 1.00±0.11 0.90±0.10 1.02±0.11 0.56
MBTPS1 1.00±0.11 1.02±0.10 0.87±0.10 0.31
1 Female C57BL/6J mice received either semipurified, low fat control diet containing 0.5%
safflower oil and 4.5% palm oil (LFC); high fat control oleic acid enriched diet
containing 4% safflower oil and 6% palm oil (HFC); or fish oil enriched diet containing
1% safflower oil and 9% menhaden oil (FO). Diets were fed from d 6 to d 13 of lactation
(n = 8). The fourth abdominal mammary gland was collected at d 13 and total RNA was
analyzed by real time PCR for the mRNA abundance of indicated genes. Gene
abbreviations are: ACACA = acetyl-coenzyme A carboxylase alpha, FASN = fatty acid
synthase, DGAT1 = diacylglycerol O-acyltransferase 1, LPL = Lipoprotein lipase, SCD1
= stearoyl - coenzyme A desaturase, S14 = thyroid hormone responsive, SREBF1-c =
sterol regulatory element binding transcription factor 1-c, SCAP= SREBF chaperone,
INSIG1 = insulin induced gene 1, INSIG2 = insulin induced gene 2, MBTPS1 =
membrane-bound transcription factor peptidase, site 1. Values represent LS means
expressed relative to LFC diet ± SE (n = 6).
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(P<0.001, Table 4.3). This was accompanied by a concomitant reduction in hepatic lipid
concentration by approximately 52% and 35% when compared with the LFC and the HFC,
respectively (Table 4.3).
Hepatic expression of several lipogenic genes was reduced; mRNA abundance for FASN,
ACACA, glycerol-3-phosphate acyltransferase (GPAM) and SCD1 were lower by 50 to 80% as
compared to the LFC and HFC treatments (P < 0.001, Figure 4.2). Among genes related to the
regulation of the transcription of lipogenic genes, there was no treatment difference in the
mRNA abundance for SREBF1-c (P = 0.39); however, the mRNA abundance for S14 and IN-
SIG1 was 60 - 75% lower for hepatic tissue from FO group as compared to the lactating dams
on the LFC and the HFC treatments (Figure 4.2 and 4.3; P < 0.001). The mRNA abundance
for SCAP also tended to be lower (32%; P = 0.1) for the FO group. On the other hand, there
was no treatment effect on the mRNA abundance of genes involved in FA oxidation includ-
ing peroxisome proliferator-activated receptor alpha (PPARa), carnitine palmitoyltransferase
1a (CPT1a), acyl-Coenzyme A oxidase 1, palmitoyl (ACOX1), fatty acid translocase (CD36)
and fatty acid binding protein 1 (FABP1) (Figure 4.4).
4.4 Discussion
Dietary PUFAs, particularly the LC ω-3 PUFAs, have several unique metabolic effects in-
cluding effects on lipid metabolism. These effects have been most extensively investigated
in the liver of rodents where the LC ω-3 PUFAs have been shown to suppress hepatic lipo-
genesis and TG synthesis while inducing peroximal and microsomal FA oxidation [63, 182–
184, 186, 194]. Although liver is considered to be central body regulator of lipid metabolism,
the relative contribution of the lipogenic tissues to total FA synthesis depends on the species
and the physiological status of the animal. For example, liver and adipose tissue contribute
about equally to total FA synthesis in the virgin mouse, but by mid-lactation the mammary
gland accounts for approximately 75% of the total rate of FA synthesis [20]. Moreover, in
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Figure 4.2: Treatment Effect on Expression of Genes Involved in Hepatic Lipid Synthesis.
Female C57BL/6J mice received either semipurified, low fat control diet containing 0.5% saf-
flower oil and 4.5% palm oil (LFC); high fat control oleic acid enriched diet containing 4%
safflower oil and 6% palm oil (HFC); or fish oil enriched diet containing 1% safflower oil and
9% menhaden oil (FO). Diets were fed from d 6 to d 13 of lactation (n = 8). Liver samples
were collected at d 13 and total RNA was analyzed by real time PCR for the mRNA abun-
dance. Gene abbreviations are: ACACA = acetyl-Coenzyme A carboxylase alpha, FASN =
fatty acid synthase, SCD1 = stearoyl-coenzyme A desaturase, GPAM = glycerol-3-phosphate
acyltransferase, mitochondrial, and S14 = thyroid hormone responsive spot 14. Each bar
represents the mean ± SE (n = 6). Significant statistical differences are indicated by different
letters among treatment for a specific gene; P < 0.01.
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Figure 4.3: Treatment Effect on Expression of Genes Involved in Transcription of Hepatic
Lipogenic Genes. Female C57BL/6J mice received either semipurified, low fat control diet
containing 0.5% safflower oil and 4.5% palm oil (LFC); high fat control oleic acid enriched
diet containing 4% safflower oil and 6% palm oil (HFC); or fish oil enriched diet containing
1% safflower oil and 9% menhaden oil (FO). Diets were fed from d 6 to d 13 of lactation (n
= 8). Liver samples were collected at d 13 and total RNA was analyzed by real time PCR
for the mRNA abundance. Gene abbreviations are: SREBF1-c = sterol regulatory element
binding transcription factor 1-c, SCAP = SREBF chaperone, INSIG1 = insulin induced gene
1, INSIG2= insulin induced gene 2, and MBTPS1 = membrane-bound transcription factor
peptidase, site 1. Each bar represents the mean ± SE (n = 6). Significant statistical differences
are indicated by different letters among treatment for a specific gene with P values as follows:
SREBF1-c = 0.39 , SCAP = 0.1, INSIG1 = <0.001, INSIG2 = 0.62, MBTPS1 = 0.62.
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Figure 4.4: Treatment Effect on Expression of Genes Involved in Hepatic FA Oxidation.
Female C57BL/6J mice received either semipurified, low fat control diet containing 0.5%
safflower oil and 4.5% palm oil (LFC); high fat control oleic acid enriched diet containing 4%
safflower oil and 6% palm oil (HFC); or fish oil enriched diet containing 1% safflower oil and
9% menhaden oil (FO). Diets were fed from d 6 to d 13 of lactation (n = 8). Liver samples were
collected at d 13 and total RNA was analyzed by real time PCR for the mRNA abundance.
Gene abbreviations are: PPARa = peroxisome proliferator activated receptor alpha, CPT1a
= carnitine palmitoyltransferase 1a, ACOX1 = acyl-Coenzyme A oxidase 1, palmitoyl, CD36
= fatty acid translocase, and FABP1 = fatty acid binding protein 1. Each bar represents the
mean ± SE (n = 6). There were no significant statistical differences; P > 0.4.
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lactating mice the mammary gland is capable of synthesizing an amount of TG equivalent to
the entire weight of the animal in a 20-d lactation cycle causing Rudolph et al. [195] to refer
to the mammary gland as a “lipid synthesizing machine”. However, little attention has been
focused on the effects of dietary LC ω-3 PUFAs on mammary lipogenesis, although milk fat
synthesis is known to be regulated by other bioactive FA [6]. Therefore, the objective of the
current experiment was to investigate the effect of dietary LC ω-3 PUFAs on lipogenesis in
the mammary gland of lactating mice. To achieve this goal, a FO supplement was used as
a dietary source of LC ω-3 PUFAs and we determined its effect on the proportion of milk
FA synthesized within the gland, the in vitro mammary lipogenic capacity of the mammary
gland and the mRNA abundance of lipogenic genes in the mammary gland. Therefore, lac-
tating mice were fed a diet containing 10% total oil and compared the FO diet as source of
LC ω-3 PUFAs with a control diet consisting of a vegetable oil blend enriched in oleic acid.
Because mammary lipogenesis might be naturally depressed by high dietary oil level, we
also included a third treatment group where mice were fed a low fat diet (5% vegetable oil
blend).
In the current study, the lipogenic capacity of mammary explants was measured and re-
sults demonstrated that rates of 14C glucose incorporation into lipids were similar among
treatment groups (P = 0.97). To confirm these results, the FA composition of the milk fat was
analyzed to determine the contribution of DSFAs. Milk short-chain (4 to 8 carbons) and MC-
FAs (10 to 14 carbons) are generally not supplied by the diet so these arise almost exclusively
by de novo synthesis from glucose within the mammary epithelial cell as a result of tissue-
specific modification of the universal FASN reaction [14]. Consequently their proportion in
milk can be taken as a proxy for the rate of mammary de novo lipid synthesis compared to
other sources [132]. Comparison of the FA profile showed no differences among treatments
in the proportion of FA less than C16 (P = 0.21). Fat is the major energy component of milk
and the growth rate of the nursing pups is correlated with milk fat production [196–198]; we
observed no difference among dietary treatments for litter weight (P = 0.70) or weight gain
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(P = 0.59) during the 7-d experimental period. Others have also observed that FO supple-
mentation to lactating rodents had no negative effect on litter growth rates [65, 68]. Taken
together the results in the current study suggest neither the rates of mammary de novo lipid
synthesis nor milk production parameters were affected by dietary FO supplementation.
The effect of LC ω-3 PUFAs on lipogenic genes has not been examined previously for
lactating mammary tissue, but in hepatic tissue the mechanism involves effects on the SREBF
system with corresponding decreases in the mRNA abundance and the activity of lipogenic
genes [63,185,186,199]. In the present study we observed that the gene expression profile for
lactating mammary tissue showed no treatment effect for the mRNA abundance of ACACA
(P = 0.53) and FASN (P = 0.25), two key enzymes in the FA synthesis pathway. Moreover,
DGAT1 mRNA abundance did not differ between FO and HFC group. Thus, there was no
evidence that dietary supply of LC ω-3 PUFAs resulted in downregulation of the expression
of lipogenic genes, and these results are consistent with the absence of dietary effects on the
growth rates of the nursing pups, the in vitro lipogenic capacity of mammary explants and
the milk fat profile of de novo synthesized FA. Nevertheless, the LC ω-3 PUFAs supplied
by the FO diet were taken up and utilized by the mammary epithelial cells as evident by
increases in the milk fat content of EPA and DHA.
The LC ω-3 PUFAs in FO have been well established as negative regulators of hepatic FA
biosynthesis in non-lactating rodents. Investigations have consistently shown effects of FO
or EPA and DHA on the SREBF system and corresponding decreases in mRNA abundance
and activity for key lipogenic enzymes [63, 185, 186, 199]. In the present study there were
distinct treatment effects on lipid metabolism in the liver from the lactating dams which dif-
fered markedly from the results with mammary tissue. FO treatment decreased liver weight
by about 20 to 25% compared to the other two dietary groups (P < 0.001) and this decrease co-
incided with an approximate 50% reduction in hepatic lipid concentration in the FO-treated
mice (P < 0.001). FO supplementation has been reported previously to decrease hepatic lipid
deposition and that was attributed to several mechanisms including downregulation of de
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novo lipid synthesis and/or enhanced FA oxidation [63, 183, 185, 186, 194]. In the present
study the reduction in hepatic fat deposition paralleled a significant decrease in mRNA lev-
els of the key enzymes in the de novo FA synthesis pathway. The mRNA abundance for
ACACA, FASN and GPAM as well as SCD1 and S14 were decreased in the FO treatment
group by 70% to 80% and 50% to 70% compared to LFC and HFC groups, respectively.
The LC ω-3 PUFAs also enhance hepatic FA oxidation in non-lactating rodents and this
coincided with increases in the mRNA abundance for PPARa and genes involved in FA traf-
ficking and oxidation in mitochondria and peroxisomes [182–184, 186, 187, 200]. However,
alterations in FA oxidation do not appear to play a significant role in the hepatic lipid at-
tenuating effect of FO we observed for lactating mice. The mRNA abundance of CPT1a and
ACOX1, key enzymes in the mitochondrial and peroxisomal β-oxidation, respectively, was
unaffected by the FO diet. Likewise the mRNA levels for CD36 and FABP1, the FA trans-
porter and trafficking proteins in liver, did not differ among dietary treatments. These genes
are regulated primarily by the PPARa nuclear receptor which functions as a hepatic lipid
sensor responding to the influx of FA by stimulating the transcription of PPARa-regulated
genes [201] and we observed no effect of the FO diet on PPARa mRNA abundance. For a
complete evaluation, quantitation of protein levels and enzyme and transcription factor ac-
tivity data would be required; nevertheless, in the current study the absence of a FO effect
on the expression level of PPARa and its regulated genes in the liver from lactating mice
suggests that the PPARa and the FA oxidation pathway were not activated.
Overal, the downregulation of hepatic lipogenesis, but not an enhanced FA oxidation,
appears to be the determining factor in the lipid ameliorating effect of FO supplementa-
tion in the current study. In an effort to outline the probable mechanism of LC ω-3 PUFAs
on hepatic lipid metabolism, Harris and Bulchandani [182] evaluated 42 rat studies where
the effects of LC ω-3 PUFAs (FO, EPA or DHA individually) were tested on hepatic lipid
metabolism. The clearest signal from the reviewed studies was that LC ω-3 PUFAs consis-
tently downregulated hepatic lipogenesis; lipogenesis was inhibited every time ω-3 PUFAs
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were fed to rats. Stimulation of β-oxidation may also be relevant but only 33 out of 47 exper-
iments found it to be increased; thus the inconsistency in these findings call this particular
pathway into question. In agreement with the present study, Tanaka et al. [186] reported
that EPA treatment markedly attenuated liver TG level in mice and significantly decreased
the mature SREBF1 levels and lipogenic gene expression; however, there were no effects on
hepatic peroxisome proliferation or mitochondrial β-oxidation. Also, Ukropec et al. [202] re-
ported that the enzyme activity of CPT-1a was not effected by ω-3 PUFAs supplementation.
Moreover, Arai et al. [187] found no effect of menhaden oil or tuna oil on expression level of
two PPARa target genes, ACOX1 and UCP2. However, these results contradict other reports
of significant upregulation of the mitochondrial and peroxisomal palmitoyl-CoA oxidation
rates and activity levels of various FA oxidation enzymes in rats fed FO or purified EPA and
DHA [183, 184, 200].
The lipogenic enzymes are known to be regulated primarily at the transcription level
under the control of SREBF1-c, the master regulator of lipid homeostasis [203], and their
activities are strongly correlated with mRNA abundance [183]. SREBF1-c belongs to the
SREBFs family of membrane-bound transcription factors that regulate enzymes responsible
for cholesterol, FA, and TG synthesis [104]. We examined the effect of dietary treatment on
mRNA of SREBF1-c and interestingly the expression was similar among treatments in both
mammary (P = 0.55) and liver (P = 0.43). Nevertheless, there was clear downregulation in
the mRNA abundance of SREBF-1c target genes in the liver of the FO group. SREBFs are
synthesized as precursors bound to the endoplasmic reticulum (ER) and nuclear envelope;
upon activation, SREBFs are released from the membrane and travel to the golgi where a ma-
ture protein is released by a sequential two-step cleavage process [203]. This mature SREBF
then enters the nucleus where it binds to the sterol regulatory elements [204, 205] in the pro-
moter region of target genes thereby increasing their expression levels. Therefore, results
in the present study are consistent with FO regulating the SREBF1-c expression posttrans-
lationally by decreasing the amount of its active nuclear form. Indeed, Yahagi et al. [104]
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demonstrated that feeding mice FO (sardine oil, rich in EPA, or tuna oil, rich in DHA) for 7
d caused a significant decrease in the amount of hepatic nuclear SREBF (nSREBF1) protein
compared with feeding either saturated (tristearin) or monounsaturated (triolein) fat. Inter-
estingly, they observed no effect on either SREBF1-c mRNA or membrane-bound precursor
protein levels. Thus, Yahagi et al. [104] and Tanaka et al. [186] concluded that LC ω-3 PUFAs
appear to regulate abundance of nSREBF protein mainly at a post-translational level.
To test the hypothesis that LC ω-3 PUFAs regulates the nSREBF1-c abundance, we deter-
mined the mRNA level of key genes in the SREBF processing pathway. INSIG1 and INSIG2
are membrane proteins of the ER that play a central role in the feedback control of lipid syn-
thesis in animal cells. INSIG’s regulate lipid synthesis by binding to SCAP, an escort protein
required for the cleavage and activation of the SREBF family. Binding of INSIG’s to SCAP
leads to ER retention of the SCAP and SREBFs complexes, preventing the proteolytic gener-
ation of the transcriptionally active nSREBFs, thereby limiting transcription of SREBF target
genes [206]. In the present study, there was no treatment effect on INSIG2 mRNA in either
liver (P = 0.62) or mammary tissue (P = 0.56). However, with FO treatment hepatic level of
INSIG1 mRNA abundance decreased by almost 75% and 65% compared to LFC and HFC re-
spectively (P < 0.001). A similar effect of LC ω-3 PUFAs on hepatic expression of INSIG1 has
been reported previously [186, 187]. In contrast, there was no effect on INSIG1 in the mam-
mary gland (P = 0.87). Theoretically the reduction in hepatic INSIG1 would not be expected
given the strong downregulation in the SREBF1-c target genes in the liver which is believed
to be due to reduced nSREBF1-c level. In a study done by Engelking et al. [207], nSREBF1
levels increased by 2-fold and the hepatic content of total cholesterol and TG increased by
4- and 6- fold, respectively, in liver of INSIG1 and INSIG2 double knockout mice compared
with the control. Moreover, in the liver of transgenic mice over-expressing human INSIG1
the content of all nSREBFs was reduced with a marked reduction in the levels of mRNAs
encoding enzymes required for synthesis of cholesterol, FA, and TG [206]. However, INSIG1
itself was identified as a SREBF target gene using micro-array analysis of mRNA from the
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mouse liver [208] whereas INSIG2 was not [208,209]. INSIG1 mRNA is expressed at high lev-
els when nSREBF levels are high as a result of sterol deprivation and the expression declines
drastically when cells are overloaded with sterols [209]. This provides a feedback mechanism
to decrease or increase the SREBF cleavage and hence the nSREBF abundance. Therefore, the
downregulation of in the current study might provide a feedback mechanism to increase
SREBF cleavage and hence can be seen within the context of the reduced abundance effect of
nSREBF1-c which add support to FO downregulating effect on the nSREBF1-c and its target
genes in the liver.
In conclusion, the present study demonstrates that dietary FO supplementation had no
effect on different mammary lipogenic parameters; mammary lipogenic capacity, level of
DSFAs and mammary lipogenic gene expression were not significantly affected by FO treat-
ment. In contrast, the FO effect on hepatic lipogenesis was obvious and resulted in impres-
sive decrease in hepatic lipid accumulation and downregulation of lipogenic gene expres-
sion. Our investigation is among the first to examine this at the cellular level in lactating an-
imals but others have observed the same downregulation of lipogenesis in liver of growing
rodents fed a diet high in LC ω-3 PUFAs. Thus, the present study highlights the importance
of the tissue specific effects of LC ω-3 PUFAs on lipogenic pathway. The exact mechanism
behind the differential effects of LC ω-3 PUFAs remains to be established.
Chapter 5
CLA Effect on Gene Expression of CLA-Induced
MFD in Lactating Ewe
5.1 Introduction
Conjugated linoleic acid (CLA) is a generic term used to describe positional and geomet-
ric isomers of linoleic acid. A number of CLA isomers are naturally produced by rumen
bacteria as intermediates in the biohydrogenation of dietary polyunsaturated fatty acids
(PUFA), with cis-9, trans-11 CLA being the predominant isomer found in ruminant-sourced
foods [32]. CLA isomers also originate from industrial hydrogenation and cis-9, trans-11 and
trans-10, cis-12 are the two isomers that have been most extensively studied [4]. Research
over the last decade has established the CLAs as unusual bioactive fatty acids (FAs) that
exert a range of biological effects in different tissues and species including antiobesity, anti-
carcinogenic, antidiabetigenic, and antiatherogenic effects [4,48]. Baumgard et al. [135] were
the first to demonstrate that trans-10, cis-12 CLA resulted in a reduction in milk fat synthesis
in lactating dairy cows, and this discovery provided a basis to explain the cause of diet-
induced milk fat depression (MFD) , a syndrome in lactating cows that had perplexed dairy
producers and scientists for over a century [132].
The molecular mechanism behind CLA-induced MFD is not completely resolved; how-
ever, the phenotypic characterization provides key insight into the functional mechanism.
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In CLA-induced MFD in dairy cows, fat is the only milk component inhibited with trans-10,
cis-12 CLA treatment. Furthermore, the reduction in milk fat secretion involves FAs of all
chain lengths, but effects are particularly pronounced for de novo synthesized fatty acids
(DSFAs) [6]. Although few studies have examined the effects of CLA on mammary lipid
metabolism at the cellular level, results have clearly shown a coordinated downregulation
in transcript abundance and/or enzymatic activity for lipogenic enzymes involved in the
uptake, de novo synthesis, desaturation, and esterification of FAs in the mammary gland
of lactating cows [9, 136, 210, 211] and laboratory animals [212–215]. Molecular mechanisms
mediating the inhibitory effect of trans-10, cis-12 CLA on mammary lipogenesis have not
been extensively investigated, but results support a central role for sterol regulatory element
binding transcription factor (SREBF) family [9, 143, 210].
CLA-induced MFD has also been observed in small ruminants including sheep [12, 216]
and goats [217, 218]. Although ruminants share similarities in many aspects, distinct dif-
ferences exist related to ruminal lipid metabolism and the relative sensitivity of mammary
lipogenic processes [219], and this might modify the mammary response to CLA treatment.
For example, in lactating goats diet-induced MFD resulted in 18 to 32% reduction in the DS-
FAs with effects being independent of mammary expression or activity of acetyl-coenzyme
A carboxylase alpha (ACACA) and fatty acid synthase (FASN) [220–222].
Dairy ewes may represent a good model to examine the mechanism of CLA-induced
MFD. They are relatively available, cost effective, manageable in size, and daily milking al-
lows a quantitative evaluation of treatment effects on milk fat yield and FA composition.
Furthermore, the relationship between trans-10, cis-12 CLA dose and the reduction in milk
fat output is similar to cows when dose is expressed on a metabolic body weight (BW) ba-
sis [12, 216]. To date, the molecular basis for MFD, whether induced by diet or CLA supple-
mentation, has not been investigated in lactating ewes. Therefore, the objective of the current
study was to investigate the molecular mechanism mediating MFD in lactating ewes fed a
CLA supplement containing trans-10, cis-12 CLA isomer. For this purpose, we used tissue
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samples obtained from lactating ewes that were fed a rumen-protected CLA supplement for
10 wk. A companion paper reports results for CLA effects on performance, organ weight
and carcass composition [223].
5.2 Material and Methods
5.2.1 Animals and Treatments
All experimental procedures involving lactating ewes were conducted at Harper Adams
University College, (Edgemond, UK) in accordance with the UK Animals (Scientific Pro-
cedures) Act 1986. Detailed procedures are reported in the companion publication [223].
Briefly, at d 16 ± 1.6 (mean ± SE) postpartum multiparous Friesland and British Milk Sheep
ewes were randomly allocated to two treatments (8/treatment) based on their breed, milk
yield and milk fat yield as measured in the previous 7 d, BW and body condition score. Ewes
were milked twice daily and fed a basal ration (0.55 : 0.45 concentrates to forage ratio, dry
matter basis) that was composed mainly of hay, rolled barley, and dried molassed sugarbeet
feed [223]. The dietary metabolizable energy and crude protein averaged (per kg DM) 10.9
Mj and 156 g, respectively, with fresh feed offered once per day at 1.05x ad libitum intake.
Treatments for the present study involved diets that were supplemented with CLA at two
levels: no CLA (Control; CON) or 15 g/d of CLA supplement (+CLA). The CLA was pro-
vided by a lipid-encapsulated CLA supplement that contained two CLA isomers in equal
proportions, cis-9, trans-11 and trans-10, cis-12 (Lutrell R©; BASF SE, Ludwigshafen, Ger-
many). The CLA supplement provided 1.5 g/d of trans-10, cis-12 and an equal amount of
cis-9, trans-11 CLA. Ewes received the two experimental treatments throughout a 10 wk pe-
riod in a randomized block design. In the companion publication there was a third treatment
(40 g/d CLA supplement) which was not included in the present study. With the exception
of milk fat, the phenotype between the CON and +CLA treatments was comparable after 10
wk of treatment, whereas the 40 g/d CLA group differed in milk yield, milk protein yield
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and BW change.
At the end of the experimental period, ewes were slaughtered over a 72 h period by
stunning and exsanguination. Subsamples of mammary secretory tissues from the left side
of the mammary gland were immediately dissected and cubes were prepared. The cubes
(≤0.5 cm) were immediately placed in a 15 ml disposable sample tube and immersed in 5 ml
of RNAlater solution (RNAlater tissue collection: RNA stabilization solution, Ambion, Inc,
USA). After sample tubes were stored at 4 0C for 24 h, the RNAlater solution was decanted
and tissue samples were blotted to remove excess solution, transferred into a 2 ml eppendorf
tube, and stored at -80 0C.
Milk was analyzed for fat and protein [216], with lipids extracted and FA methylated and
analyzed by a gas chromatograph using a fused-silica capillary column [CP-Sil 88; 100m x
0.25mm (i.d.) Varian] [12]. In the calculation of yield for milk FAs, the glycerol in milk fat
was accounted for according to Schauff et al. [224].
5.2.2 RNA Extraction and Real-Time PCR
Total RNA was extracted and purified from∼ 30 mg of mammary tissue following the Qiagen
RNA extraction and clean-up protocol using RNeasy Lipid kit (Qiagen, Valencia, CA). The
potential genomic DNA co-extraction with RNA was excluded through on-column DNase
treatment (RNase-Free DNase Set; Qiagen). Purity of total RNA from each sample was ver-
ified using 260 nm/280 nm absorbance ratio with background correction at 320 nm using
Beckman DU-640 spectrophotometer (Beckman Coulter, Inc., Brea, CA, USA). RNA con-
centration and quality were determined by 2100 BioAnalyzer (Agilent Technologies, Santa
Clara, CA). Two µg total RNA were reverse transcribed using High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Carlsbad, California) with random primers. Quan-
titative real-time PCR (qRT-PCR) assays were developed for genes of interest (Table A.2).
qRT-PCR reaction included Power SYBR R© Green PCR Master Mix (Applied Biosystems)
and 400 nmol/L of gene-specific forward and reverse primers (Invitrogen, Carlsbad, Cali-
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fornia). Twenty five ng cDNA were amplified using a 2-step program (95◦C for 15 s and
60◦C for 60 s) with an ABI PRISM 7000 sequence detection system (Applied Biosystems).
The specificity of the primers was verified by presence of a single product in the dissocia-
tion curves at the end of amplification process. A standard curve was derived from serial
dilutions of pooled cDNA from mammary or liver tissues. Relative mRNA concentrations
were expressed in arbitrary units and the logarithms (base 10) of concentrations were plot-
ted against the threshold cycles (CTs). The resulting least square fit was used as the standard
curve to derive the arbitrary concentration for each sample.
All primers were designed from ovine specific sequence data in the International Sheep
Genomics Consortium (ISGC) [225] and National Center for Biotechnology Information (NCBI)
data bases if available. Care was taken to design primers pairs that amplify both bovine and
ovine sequences to add extra layer of confirmation. For gene sequences that are not avail-
able for sheep, primers were designed from closely related species including cow, horse, mice
and human. Briefly, Nucleotide sequences for cDNA of genes of interest across species were
aligned using Clustal W running under Bioedit (version 7.0.9) [226] and highly conserved se-
quences were selected for primer designing using Primer3Plus [162]. Primers were designed
to span exon boundaries when possible. The primer sequence used for the expression of
mRNA are presented in Table A.2.
5.2.3 Statistical Analysis
Data were analyzed by Student’s or unequal variance unpaired t-test in R statistical pack-
age [166]. A normalization factor [193] was generated from five house-keeping genes (18S
ribosomal RNA (18S), actin, beta (ACTB), ribosomal protein S13 (RPS13), ribosomal protein
S15 (RPS15) and ribosomal protein L13a (RPL13A), Table A.2) and used to normalize gene
expression data. Few points were considered outliers and excluded in analysis and rarely
more than one per response variable. In a few cases data were log transformed to meet the
statistical test assumptions.
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5.3 Results
5.3.1 Performance-Related Variables
Effects of dietary treatment on performance parameters of the lactating ewes at wk 10 of
treatment are presented in Table 5.1. There were no treatment effects on feed intake, BW
or body condition score between animals in the control group and those receiving the CLA
supplemented diet. Similarly, there were no treatment effects on milk yield or milk compo-
sition for protein or lactose at wk 10 of the study. In contrast, CLA treatment significantly
decreased both milk fat concentration (g/100 g) and milk fat yield (g/d) by almost 22% when
compared to the control group.
A comparison of effects of CLA supplement on the FA composition of milk fat demon-
strated that the proportions of several FAs were altered (Table 5.2). Specifically, proportions
of C6:0, C8:0, C10:0 and C12:0 were reduced for the CLA supplemented treatment whereas
C18:0, cis-9, trans-11 CLA and trans-10, cis-12 CLA were increased. Effects of CLA treatment
were further examined by grouping milk FA according to source and comparing the profile
(Figure 5.1) and yield (Figure 5.2). CLA treatment had the greatest effect on de novo synthe-
sized FAs (<16 carbons) with significant decreases in the proportion (15%; P = 0.04) and the
daily yield (27%; P < 0.04). CLA treatment resulted in an increase in the proportion of FAs
> C16 (27%, P = 0.04) and numerical decreases (non-significant) in the yields of 16 carbon
FAs (15%; P = 0.29) and the yield of >16 carbon FAs (6%; P = 0.71).
5.3.2 Gene Expression
The effect of dietary treatment on the expression of genes involved in mammary lipid syn-
thesis is presented in Figures 5.3 and 5.4. The expression of several lipogenic genes were
strongly reduced by CLA treatment with the mRNA abundance ofACACA, FASN and stearoyl-
coenzyme A desaturase 1 (SCD1) being lower by 35 to 55% in the CLA treated group as
compared to the control. Similarly, CLA treatment decreased the mRNA abundance of
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Table 5.1: Treatment Effect on Performance Parameters in
Dairy Ewes
Treatment1
Variable CON +CLA P Value
Body Weight (kg) 63.05±2.83 60.03±3.18 0.49
Dry Matter Intake2 (kg/d) 2.18±0.08 2.09±0.06 0.40
Milk Yield (g/d) 1028±155 1015±147 0.95
Milk Fat
g/100 g 6.15±0.35 4.83±0.19 <0.01
g/d 61.43±8.10 48.26±6.23 0.07
Milk Protein
g/100 g 4.94±0.16 4.82±0.11 0.57
g/d 49.83±7.12 48.09±6.01 0.75
Milk Lactose
g/100 g 4.70±0.06 4.77±0.06 0.47
g/d 48.8±7.78 48.55±7.15 0.97
1 Lactating ewes received either control (CON; no supplement) or
conjugated linoleic acid supplement (+CLA) for 10 wk starting on day 16
postpartum. During treatment, wk 10 BW and milk yield were
determined and milk samples were collected and analyzed. Values
represent means and SEM for 8 ewes/treatment.
2 Average daily dry matter intake during the 10-wk experimental period
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Table 5.2: Treatment Effect on Milk FA Profile for Dairy Ewes1
Treatment
Variable CON +CLA P Value
FA(g/100 g)
4:0 2.65±0.03 2.88±0.05 <0.01
6:0 1.97±0.09 1.51±0.10 <0.01
8:0 1.82±0.12 1.23±0.12 <0.01
10:0 5.93±0.48 3.95±0.41 <0.05
12:0 3.51±0.29 2.76±0.20 <0.05
14:0 9.12±0.53 9.32±0.35 0.65
16:0 31.78±0.42 31.89±0.60 0.88
16:1, cis-9 1.17±0.06 0.93±0.06 <0.05
18:0 8.62±0.46 10.63±0.64 0.02
18:1, trans-9 0.18±0.01 0.15±0.01 0.11
18:1, trans-10 0.17±0.01 0.19±0.01 0.11
18:1, trans-11 1.05±0.08 1.13±0.06 0.24
18:1, trans-12 0.24±0.02 0.23±0.02 0.65
18:1, cis-9 19.63±0.57 20.96±0.77 0.18
18:2, cis-9, cis-12 2.08±0.10 2.16±0.11 0.61
18:3,cis-9,cis-12,cis-15 0.39±0.02 0.37±0.01 0.26
cis-9, trans-11 CLA 0.48±0.03 0.62±0.03 <0.01
trans-10, cis-12 CLA >0.01±0.00 0.08±0.01 <0.001
Desaturation Index
16:1, cis-9/(16:1, cis-9+16:0) 0.036±0.002 0.029±0.002 <0.05
18:1, cis-9/(18:1, cis-9+18:0) 0.70±0.01 0.66±0.01 0.06
1 Lactating ewes received either control (CON; no supplement) or conjugated
linoleic acid (+CLA) supplement for 10 wk starting on day 16 postpartum.
During treatment, wk 10 milk samples were collected and analyzed for FA
profile. Values represent means ± SE for 8 ewes/treatment.
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Figure 5.1: Treatment Effect on Milk FA Composition. Lactating ewes received either con-
trol (CON; no supplement; black bars) or conjugated linoleic acid supplement (+CLA; light
bars) for 10 wk starting on day 16 postpartum. Milk samples were collected and analyzed
for FA profile. FA are grouped according to source with < C16 representing de novo synthe-
sized FA, > C16 representing preformed FA taken up from circulation and C16 being derived
from both sources. Values represent means for 8 ewes/treatment with SE bars as indicated.
Significant differences indicated by asterisk (*) and treatment differences were: < C16 (P =
0.04), C16 (P = 0.88) and >C16 (P = 0.04).
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Figure 5.2: Treatment Effect on Milk FA Yield. Lactating ewes received either control (CON;
no supplement; black bars) or conjugated linoleic acid supplement (+CLA; light bars) for
10 wk starting on day 16 postpartum. Milk samples were collected and analyzed for FA
profile and yield. FA are grouped according to source with < C16 representing de novo
synthesized FA, > C16 representing preformed FA taken up from circulation and C16 being
derived from both sources. Values represent means for 8 ewes/treatment with SE bars as
indicated. Significant differences indicated by asterisk (*) and treatment differences were: <
C16 (P = 0.04), C16 (P = 0.29) and > C16 (P = 0.71).
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lipoprotein lipase (LPL), glycerol-3-phosphate acyltransferase (GPAM) and diacylglycerol
O-acyltransferase 1 (DGAT1) by about 30% compared to the control, but fatty acid bind-
ing protein 3 (FABP3) was unaffected. Among transcription factors related to regulation of
lipogenic genes, CLA treatment decreased the mRNA abundance of the sterol regulatory ele-
ment binding transcription factor 1 (SREBF1) and insulin induced gene 1 (INSIG1) by almost
60%, but there was no effect on the mRNA abundance of thyroid hormone responsive spot
14 (S14).
5.4 Discussion
Fat is the most variable component of milk and is especially responsive to nutrition, thereby
offering a practical tool to alter its yield and composition [227]. One nutritional situation of
practical and biological interest in dairy cows is diet-induced MFD. Recent work has estab-
lished that diet-induced MFD is caused by biohydrogenation intermediates produced dur-
ing rumen fermentation, and the most extensively investigated of these is trans-10, cis-12
CLA [6]. In lactating cows, the downregulation of mammary lipid synthesis is the most
important biomarker in the CLA-induced MFD, and fat is the only milk component inhib-
ited with trans-10, cis-12 CLA treatment [6]. While the mechanism for CLA-induced MFD
is not fully understood in dairy cows [228], the ability of CLA to induce MFD has also been
observed in lactating ewes [12, 216]. Further, when extrapolated to the sheep metabolic live-
weight basis, the dose response relationship of daily CLA intake and MFD was similar to
that reported for dairy cows. Therefore, the objective of the present investigation was to
consider dairy ewes as a model and conduct an initial examination of the mechanism for
CLA-induced MFD.
Consistent with previous investigations with dairy cows, CLA treatment in the current
study significantly decreased both milk fat concentration and milk fat yield by almost 22%.
This reduction is similar to the 17% decrease that is predicted from utilizing the milk fat
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Figure 5.3: Treatment Effects on Expression of Genes Involved in De Novo Synthesis and
Uptake of Preformed FAs. Lactating ewes received either control (CON; black bars; no
supplement) or conjugated linoleic acid supplement (CLA; light bars) for 10 wk starting on
day 16 postpartum. Mammary gland samples were collected at the end of the treatment and
total RNA was analyzed by qRT-PCR for the mRNA abundance of indicated genes. ACSS1
= acyl-CoA synthetase short-chain 2, ACACA = acetyl-coenzyme A carboxylase alpha, FASN
= fatty acid synthase, SCD1 = Stearoyl-coenzyme A desaturase 1, LPL = lipoprotein lipase,
FABP3 = fatty acid binding protein 3. Each bar represents means for 8 ewes/treatment with
SE bars as indicated. Significant differences indicated by asterisk (*) and treatment P values
were: ACSS1 = 0.17, ACACA = 0.01, FASN = 0.02, SCD1 = 0.01, LPL = 0.06, FABP3 = 0.50.
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Figure 5.4: Treatment Effect on Expression of Genes Involved in Transcription Regulation
and FAs Esterification. Lactating ewes received either control (CON; no supplement; black
bars) or conjugated linoleic acid supplement CLA; light bars for 10 wk starting on day 16
postpartum. Mammary gland samples were collected at the end of the treatment and total
RNA was analyzed by qRT-PCR for the mRNA abundance of indicated genes. GPAM =
glycerol-3-phosphate acyltransferase, DGAT1 = diacylglycerol O-acyltransferase 1, SREBF1
= sterol regulatory element-binding factor 1, INSIG1 = insulin induced gene 1, S14 = thyroid
hormone responsive spot 14. Each bar represents means for 8 ewes/treatment with SE bars
as indicated. Significant differences indicated by asterisk (*) and treatment P values were:
GPAM = 0.15, DGAT1 = 0.09, SREBF1 = < 0.01, INSIG1 = 0.01, S14 = 0.72.
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concentration of trans-10, cis-12 CLA we observed for CLA-treated dairy ewes in the equa-
tion relating milk fat trans-10, cis-12 CLA concentration and the percent reduction in milk fat
yield developed for dairy cows abomasally infused with trans-10, cis-12 CLA [141]. Further-
more, the CLA effect in dairy ewes was specific for mammary lipid synthesis as there was
no treatment effects on milk yield or milk composition of protein or lactose.
The FAs in milk fat arise from either uptake of preformed FAs from circulation or de novo
synthesis within the mammary epithelial cells. For instance, short-chain FAs (4 to 8 carbons)
and medium-chain FAs (10 to 14 carbons) arise almost exclusively from de novo synthesis
in the mammary gland with acetate and to a lesser extent β-hydroxybutyrate serving as the
carbon sources [22]. On the other hand, long-chain FAs (>16 carbons) are derived from the
uptake of FAs from circulating lipoproteins (major) and non-esterified FAs (minor), while
FAs of 16 carbons in length originate from both de novo synthesis and uptake of preformed
FAs [132]. In ruminants, on a molar basis about one-half of the FAs in milk fat are derived
from each source [22]. During CLA-induced MFD in dairy cow, the reduction in milk fat
involves FAs of all chain lengths but the decrease is more substantial for those synthesized de
novo [6]. A more pronounced reduction in DSFAs has also been reported for CLA-induced
MFD in dairy ewes [12,216]. In the current study, CLA treatment significantly decreased the
yield of short and medium chain FAs (< 16 carbons) by 27% whereas milk fat output of 16
and >16 carbon FAs were less markedly reduced (15% and 6%, respectively; non-significant).
The response of dairy ewes and other lactating specie to trans-10, cis-12 CLA demon-
strates that CLA effects on lactating mammary gland are highly specific for lipid synthesis
and must include biochemical pathways of milk fat synthesis. Previous studies that have
investigated the effects of the CLA on the mammary lipid metabolism have clearly shown
a coordinated downregulation in the transcripts and/or enzymatic activities for genes in-
volved in the uptake, de novo synthesis, desaturation, and esterification of FAs in mammary
gland of both dairy cows [9, 136, 210, 211] and lactating rodents [212–215].
The present study extends this research to dairy ewes by investigating the mechanism of
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CLA treatment on mRNA abundance of genes relating to the lipogenic pathways for mam-
mary synthesis of milk fat. Three enzymes involved in de novo lipogenesis were examined:
1) acyl-CoA synthetase short-chain 1 (ACSS1), the cytosolic enzyme that catalyzes the acti-
vation of acetate, 2) ACACA, the biotin containing enzyme that catalyzes the formation of
malonyl-CoA, and 3) FASN the multifunctional protein that catalyzes the use of malonyl-
CoA to form saturated FAs. The mRNA abundance for ACSS1, ACACA and FASN was de-
creased by 35 to 55% in the mammary tissue from ewes receiving the CLA supplement. In
the biochemical pathway for the use of preformed FAs we examined LPL , whose primary
function is the hydrolysis of triglycerides in circulating chylomicra and very low density
lipoproteins, and FABP3 that is involved in the uptake and intracellular transport of FAs.
The mammary abundance of LPL was reduced by 32% in the CLA treatment group whereas
mRNA abundance for FABP3 was unchanged. About two-thirds of the stearic acid taken up
by the mammary gland is converted to oleic acid by the SCD1 [6] and in the present study
mammary mRNA abundance of SCD1 was reduced over 40% in the CLA treated group. The
FAs in milk fat are mainly secreted as triglycerides and two key enzymes involved in the
esterification were also examined, GPAM and DGAT1 [22, 23]. CLA treatment decreased the
mRNA abundance of GPAM and DGAT1 by almost 30% compared to the control. Overall,
the present study examined a number of the key enzymes involved in milk fat synthesis and
observed that mRNA abundance for most was reduced as a result of the 10 wk treatment
with trans-10, cis-12 CLA. Wherever values for the same enzymes have been reported, sim-
ilar decreases in mammary mRNA abundance have been reported for trans-10, cis-12 CLA
treatment of dairy cows [9, 136, 210, 211] and lactating rodents [212, 213, 215].
The molecular mechanisms mediating the CLA-induced inhibition of milk fat synthe-
sis are not well understood, but a role for the SREBF family of transcription factors was
proposed [211], based on their function as global regulators of expression for many genes in-
volved in lipid synthesis [203,229]. The SREBF are synthesized in the endoplasmic reticulum
where they are anchored by INSIG1. To effect transcription, the SREBF must be trafficked
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to the golgi where the an active N-terminal fragment is released by proteolytic cleavage
thereby allowing for nuclear translocation. A role for SREBF1 was supported in studies with
a bovine mammary epithelial cell line, where trans-10, cis-12 CLA decreased abundance of
the nuclear active SREBF1 protein [143]. Subsequent studies showed a downregulation of
SREBF1 and INSIG1 in milk fat depressed cows that were receiving trans-10, cis-12 CLA sup-
plements [9, 210]. Consistent with these results, CLA treatment of lactating ewes decreased
the mammary mRNA abundance of the SREBF1 and INSIG1 by almost 60% in the present
study. However, CLA treatment has also caused a reduction in mammary mRNA for S14
in lactating cows [9] and mice [212], but there was no effect of CLA treatment on mRNA
abundance of S14 in the present study. The exact role of S14 in the regulation of lipogene-
sis is unknown, but a number of reports have demonstrated that mRNA expression of S14 is
highly responsive to changes in lipogenesis in adipose tissue and liver (summarized by Cun-
ningham et al. [230]), as well as the aforementioned studies with mammary tissue. Thus, the
lack of an effect in the present study was unexpected and we have no explanation for the
difference.
In summary, the present study demonstrated that CLA supplements to lactating ewes
resulted in a decrease in milk fat secretion with DSFAs being most markedly affected. Con-
sistent with this, a coordinated downregulation in the mRNA expression of key enzymes
involved in de novo lipogenesis occurred. These reductions were associated with the SREBF
transcription system based on the corresponding reduction in the mRNA expression of SREBF1
and INSIG1, and the fact that the genes for the effected enzymes contain a sterol response
element in their promoter region [77, 208]. Overall, the ewe represents a good model to ex-
amine fat synthesis in the mammary gland, and the CLA-induced milk fat depression in the
lactating ewe appears to occur by mechanisms similar to other species.
Chapter 6
Integrated Discussion and Summary
Recent research has established that some nutrients can act as signaling molecules and through
appropriate cellular sensing mechanisms these dietary signals are translated into changes in
gene, protein, and metabolite expression [2]. Bioactive fatty acids (FAs) are among these
and the information that allows nutrients to activate specific signaling pathways is con-
tained within their molecular structure. Minor changes in this structure, e.g. the number,
position and/or geometry of the double bonds, can have a profound influence on the bioac-
tivity of the FAs and on which sensor pathways are activated. De novo lipogenesis (DNL)
is a critical process that is implicated in wide range of physiological and pathological pro-
cesses. As reviewed in Chapter 2, DNL from simple substrates, glucose and acetate in mono-
gastrics and ruminant animals respectively, requires collaboration and harmony of multiple
metabolic pathways. This diverse array of metabolic pathways and their key enzymes are
highly active in liver, adipose tissue and the lactating mammary glands and, interestingly,
in many human tumors. Although liver is considered to be central body regulator of lipid
metabolism, the relative contribution of the lipogenic tissues to total FA synthesis depends
on the species and the physiological status of the animal. For example, in lactating mice
the mammary gland is capable of synthesizing an amount of triglyceride equivalent to the
entire weight of the animal in a 20-d lactation cycle [195]. In addition to genetic, hormonal
and transcriptional control, DNL is nutritionally regulated and highly responsive to dietary
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FA composition. This thesis focuses on two groups of bioactive FAs, conjugated linoleic acid
(CLA) and long chain ω-3 polyunsaturated fatty acids (LC ω-3 PUFAs). These FAs represent
unique examples of bioactive nutrients that show a wide range of functions in biological
systems including the ability to modulate gene expression [52], inflammatory processes [53]
and cellular membrane structure and function as well as signaling pathways involved in
normal and pathological cell functions [54]. CLA is a generic name for isomers of linoleic
acid that have a conjugated pair of double bonds. They are naturally produced by rumen
bacteria as intermediates in the biohydrogenation of dietary PUFAs and dietary supplemen-
tation of trans-10, cis-12 CLA markedly downregulates fat accretion in growing animals and
mammary lipid synthesis in lactating animals [6, 144]. The LC ω-3 PUFAs, eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), are essential FAs important for developmental
processes and the prevention of chronic diseases. Relative to DNL, the dietary LC ω-3 PU-
FAs are potent regulators of hepatic pathways of de novo lipid synthesis [7]. The proposed
mechanisms by which these bioactive FAs effect lipid metabolism involves regulation of the
abundance and activity of metabolic nuclear receptors and lipogenic enzymes. While the
mechanistic details are not completely elucidated, it is clear that there are specie and tissue
differences, and even differences among specific FA isomers. Therefore, the overall objective
of this dissertation was to investigate the molecular mechanisms of different bioactive FAs on
some aspects of lipid metabolism using different animal models; sheep and mice and phys-
iological status; lactation and growth. The initial investigation reported in this thesis was
designed to examine the role of thyroid hormone responsive spot 14 (S14) in the regulation
of lipid synthesis in adipose tissue of growing mice (Chapter 3). Of particular interest was
the possible role of S14 in the CLA-induced reduction in fat accretion. The S14 protein is a
small acidic protein whose exact function is not yet clear. However, several lines of evidence
suggested that it may play an important role in the regulation of lipogenesis. As reviewed in
Chapter 2, S14 is predominantly expressed in lipid synthesizing tissues and its expression is
highly correlated to rates of lipogenesis under a wide range of situations involving dietary,
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hormonal, and other treatments [34, 37, 38, 43, 45, 146–154]. Likewise, a reduction in mRNA
abundance for S14 corresponds to a trans-10, cis-12 CLA induced reduction in fat synthesis
in growing mice (body fat; [9, 145]) and lactating cows (milk fat; [9]). Based on this work
our hypothesis was that S14 was essential for normal lipogenesis in adipose tissue and that
it played a key role in the antiobesity effect of CLA. We investigated these hypotheses by
utilizing a genomic approach with wild type (Wt) and S14 null mice and treating the two
groups of mice with CLA for 14 days. We observed that knocking out the S14 gene signif-
icantly reduced the epidydemal fat depot by about 25%, but there was no corresponding
reduction in the mRNA abundance for lipogenic genes. Zhu et al. [45] observed a similar
paradox in the milk fat synthesis of S14 null mice where the rate of mammary DNL as well
as milk and mammary tissue triglyceride content were decreased; however, they reported
no effect on mRNA abundance of FASN or ACACA and, even more, the ACACA enzyme
activity was significantly increased in the lactating mammary gland of the null mice [45].
Although we observed a modest reduction in fat accretion in S14 null mice, the lack of a cor-
responding reduction in the expression of key lipogenic enzymes suggests that contrary to
our hypothesis, the S14 protein is not involved in the transcriptional regulation of lipogenic
enzymes. There could be a compensatory mechanism in response to decreased lipogenesis
that might maintain or upregulate the lipogenic gene expression. However, the decrease in
fat accretion (present study) and in mammary lipogenesis [45] in the S14 null mice would
be consistent with S14 protein regulating lipogenesis by other mechanisms in mammary and
adipose tissues. Indeed, recent data has confirmed the ability of S14 to form heterodimers
with other proteins in the cytoplasm including MIG12 which could regulate the activity of
ACACA [179]. Moreover, in the mammary gland of null mice, there was an indication of
reduction in the activity of FASN [45]. Altogether these data confirm that S14 might play a
different role in the regulation of lipogenesis, more research is required to explore the possi-
bility that the S14 protein may function to alter the enzyme activity of ACACA and perhaps
even FASN.
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In the case of CLA, we observed that trans-10, cis-12 CLA significantly reduced the total
dissected fat tissue by almost 40% in both Wt and S14 null mice with no evidence of a CLA
by genotype interaction. The fact that CLA-induced a delipidative effect regardless of the
genotype demonstrates that expression of the S14 gene is not essential for the CLA mecha-
nism. In the current study, the mRNA abundance of SREBF1-c, FASN and ACACA decreased
by almost 30% - 70% regardless of the genotype.
Therefore, contrary to our hypothesis, we found no support that S14 protein was an es-
sential component in the mechanism of the CLA delipidative effect; rather the CLA-induced
reduction in body fat accretion was clearly evident whether the genotype was Wt or S14 null.
A second focus of this thesis was to examine the effects of LC ω-3 PUFAs on lipid syn-
thesis in lactating mice (Chapter 4). Dietary PUFAs, particularly the LC ω-3 PUFAs supplied
in fish oil (FO), have several unique metabolic effects including effects on lipid metabolism.
These effects have been most extensively investigated in the liver of non-lactating rodents
where the LC ω-3 PUFAs have been shown to suppress hepatic lipogenesis and TG synthesis
while inducing FA oxidation [63, 182–184, 186, 194]. However, the effect of LC ω-3 PUFAs on
the biology of mammary gland, the major lipid synthesizing organ during lactation, has not
been investigated extensively and we are not aware of any reports on effects on mammary
enzymes involved in lipogenesis. The liver is also active in lipid synthesis during lactation
in mice [20] and this allows the simultaneous examination of the effects of LC ω-3 PUFAs on
liver and mammary tissue during this physiological state. Mice were given a diet containing
10% FO from d 6 to 13 of lactation and we found that the LC ω-3 PUFAs supplied by the FO
diet were taken up and utilized by the mammary epithelial cells as evident by increases in
the milk fat content of EPA and DHA. Furthermore, comparison of the FA profile for milk
fat showed no differences among treatments in the proportion of de novo synthesized FAs,
and the lipogenic capacity of mammary explants, measured by rates of 14C glucose incor-
poration into lipids, was similar among treatment groups. In addition, mRNA abundance of
ACACA and FASN, two key enzymes in the FA synthesis pathway were not different among
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treatments. Thus, the consistency of the mammary lipogenic gene expression profile, the
absence of treatment effects on the growth rates of the nursing pups, and other mammary
variables related to DNL provide strong evidence that LC ω-3 PUFAs do not adversely affect
rates of mammary lipogenesis. In contrast to mammary lipid synthesis, we observed dis-
tinct treatment effects on lipid metabolism in the liver from the lactating dams. FO treatment
decreased liver weight by about 20 to 25% and this decrease coincided with an approxi-
mate 50% reduction in hepatic lipid concentration in the FO-treated mice. The reduction in
hepatic fat deposition paralleled a significant decrease in mRNA levels of the key enzymes
in the DNL pathway. The activity of lipogenic enzymes is strongly correlated with mRNA
abundance [183] and these enzymes are known to be regulated primarily at the transcription
level under the control of SREBF1-c, the master regulator of lipid homeostasis [203]. In the
present study there was a clear downregulation in the mRNA abundance of SREBF1-c tar-
get genes in the liver of the FO group; the mRNA abundance for ACACA, FASN and GPAM
as well as SCD1 and S14 were decreased by 50% to 80% in the FO treatment group. These
results are consistent with FO regulating the SREBF1-c expression posttranslationally by de-
creasing the amount of its active nuclear form. To confirm this point, we determined the
mRNA level of key genes in the SREBF processing pathway. We found that FO treatment
decreased the hepatic expression of INSIG1 by more than 65% whereas there was no effect
on INSIG1 expression in the mammary gland and no effect on expression of INSIG2 in either
liver or mammary tissue. Overall, these results demonstrate that dietary FO supplementa-
tion to lactating mice had no effect on mammary lipogenic variables, but effects on hepatic
lipogenesis were obvious and resulted in an impressive decrease in hepatic lipid accumu-
lation and downregulation of lipogenic gene expression. One could speculate the absence
of LC ω-3 PUFAs effects on mammary lipogenesis provides a mechanism to give high pri-
ority to the supply of energy (milk fat) for survival of the nursing neonates. Nevertheless,
the present investigation is among the first to examine this at the cellular level in lactating
animals and results highlight the importance of the tissue specific effects of LC ω-3 PUFAs
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on the lipogenic pathways. The mechanism behind the differential tissue effects remains to
be established but will need to accommodate the fact that the LC ω-3 PUFAs are taken up by
the mammary gland and utilized in the synthesis of milk fat.
The final investigation reported in this dissertation involves the role of CLA in the reg-
ulation of milk fat synthesis (Chapter 5). Mammary lipogenesis is nutritionally regulated
and highly responsive to dietary FA composition [188]. One nutritional situation of practi-
cal and biological interest in dairy cows is diet-induced milk fat depression (MFD). Recent
work has established that the diet-induced MFD is caused by biohydrogenation interme-
diates produced during rumen fermentation, the most investigated being trans-10, cis-12
CLA [6]. Dietary supplements of trans-10, cis-12 CLA result in MFD in lactating ruminants
and non-ruminants [6]. In lactating cows, the downregulation of mammary lipid synthesis is
the most important biomarker in the CLA-induced MFD, and fat is the only milk component
inhibited with trans-10, cis-12 CLA treatment [6]. CLA-induced MFD has also been observed
in small ruminants including sheep [12, 216] and goats [217, 218]. Although ruminants share
similarities in many aspects, distinct differences exist related to ruminal lipid metabolism
and the relative sensitivity of mammary lipogenic processes [219], and this might modify
the mammary response to CLA treatment. Studies of the mechanism of CLA-induced MFD
have exclusively utilized the dairy cow [228], so the objective of the present study was to ex-
tend these results to lactating ewes. Of interest was whether aspects of the mechanism would
be similar thereby providing an opportunity to use the lactating ewe to serve as a convenient
model for future investigations. The study involved lactating dairy ewes that received a
CLA supplement containing trans-10, cis-12 CLA for 10 wks. We found that the phenotypic
effects of CLA treatment of lactating ewes were specific for mammary lipid synthesis, just
as reported for dairy cows. CLA treatment resulted in approximately 22% decrease in both
milk fat concentration and milk fat yield with no effects on milk yield or milk composition
of protein or lactose. Moreover, CLA treatment significantly decreased the yield of short and
medium chain FAs (< 16 carbons) which are unique products of de novo FA synthesis. To
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investigate the molecular mechanism of CLA effect behind this phenotype, we examined a
number of the key enzymes involved in milk fat synthesis and observed that mRNA abun-
dance for most was reduced as a result of the 10 wk treatment with trans-10, cis-12 CLA;
mRNA abundance for ACSS1, ACAC, FASN, LPL, GPAM and DGAT1 were reduced by al-
most 30% compared to the control. The molecular mechanisms mediating the CLA-induced
inhibition of milk fat synthesis are not well understood, but a role for the SREBF family of
transcription factors has been proposed [211], based on their function as global regulators
of expression for many genes involved in lipid synthesis [203, 229]. Consistent with these
results, CLA treatment of lactating ewes decreased the mammary mRNA abundance of the
SREBF1 and INSIG1 by almost 60%. Similar corresponding reductions in the expression of
lipogenic genes and members of the SREBF1 transcription factor family have been reported
previously for lactating dairy cows receiving CLA supplements [9,136,210,211] and lactating
rodents [212–215]. Overall, results demonstrated that CLA supplements to lactating ewes re-
sulted in a decrease in milk fat secretion with de novo synthesized FAs being most markedly
affected. Consistent with this, a coordinated downregulation in the mRNA expression of key
enzymes involved in DNL occurred. These reductions were associated with the SREBF tran-
scription system based on the corresponding reduction in the mRNA expression of SREBF1
and INSIG1, and the fact that the genes for the effected enzymes contain a sterol response
element in their promoter region [77,208]. Thus, the ewe is responding to the trans-10, cis-12
CLA in a manner similar to the cow and should represent a good model to continue mecha-
nistic studies of the regulation of milk fat synthesis in the mammary gland.
Appendix A
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Table A.1: Murine Primers Used in Real-Time PCR Analysis
Gene Forward primer Reverese primer
18S GTGGGCCTGCGGCTTAAT GCCAGAGTCTCGTTCGTTATC
ACOX1 AGTGCCACTGCGGTCCCTGA CAGTGATGCCTGGCAGAAGCTTG
ACACA GACCCTACACTTACTGATGAG AAGCAATAAGAACCTGACGAG
B2M CATGGCTCGCTCGGCGACC AATGTGAGGCGGGTGGAACTG
CPT1a CTCAAACCTATTCGTCTTCTG TTGGATGGTGTCTGTCTC
DGAT1 TCCGTCCAGGGTGGTAGTG TGAACAAAGAATCTTGCAGACGA
FASN AGAGATCCCGAGACGCTTCT GCCTGGTAGGCATTCTGTAGT
GPAM CGCGGGGTCAGCACATGGTT ACGAAGGGCCTCTTCCGGCT
INSIG1 CTCCGGGCAGAGCTCAGGATTTCT ACCCCGCGGATCACCACGTT
INSIG1 TCACAGTGACTGAGCTTCAGCA TCATCTTCATCACACCCAGGAC
INSIG2 GGAGTCACCTCGGCCTAAAAA CAAGTTCAACACTAATGCCAGGA
LPL GGACGGTAACGGGAATGTATG ACGTTGTCTAGGGGGTACTTAAA
MBTPS1 CTGGTGGTTTTGCTCTGTGG GGCTGTGAAGTATCCGTTGAAAG
PPARa GTCATCACAGACACCCTC TATTCGACATCGATGTTCAG
RPS13 TCCCTCCCAGATAGGTGTAATCC TCCTTTCTGTTCCTCTCAAGGT
RPS20 GAGAAGGTTTGTGCGGACTTG CCGGCTCAATACTGATGGAAG
S14 TGAGAACGACGCTGCTGAAAC AGGTGGGTAAGGATGTGATGGAG
SCD1 TGGGAAAGTGAGGCGAGCAACTG AGGGAGGTGCAGTGATGGTGGTG
SREBP-1c GGAGCCATGGATTGCACATT GGCCCGGGAAGTCACTGT
SCAP TGGAGCTTTTGAGACTCAGGA TCGATTAAGCAGGTGAGGTCG
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Table A.2: Ovine Primers Used in Real-Time PCR Analysis1
Gene Forward primer Reverese primer
18S GATCCATTGGAGGGCAAGTCT GCAGCAATTTAATATACGCTATTGG
ACTB GCGTGGCTACAGCTTCACC CTTGATGTCACGGACGATTTC
ACAC TTTCCTAAATTTTTCACGTTCC AGGCTCCAGGTGACGATAGA
ACSS1 TGAGCCTGGAACTGAAGTGA GACTCCATACCTCTTGAGTGTGTT
DGAT1 GTTCCTCACCCAGCTCCAG GATGAGCCAGATGAGGTGGT
FABP3 GGACAGCAAGAATTTCGATGA CGATGATTGTGGTAGGCTTG
FASN TGGTGACAGATGATGACAGG GAAGAAGGAAGCGTCAAACC
INSIG1 GTCATCGCCACCATCTTCTC GACTGTCGATGCAGGGGTA
LPL ACCTGAAGACTCGTTCTCAGATG GGCCTGGTTGGTGTATGTATT
MGPAT GCATTGGTCGGTGTAAGCAT TTCTTTCCACTTCAAGGTTGC
RPL13A AGCCACCCTGGAGGAGAAGCG TTTCGGCCTGCTTCCGTAGCC
RPS15 CGGCAAGATGGCGGAAGTGGAAC TGGCGCGCGCTGTATAGCTG
RPS20 TTCACCGGATTAGGATCACC CTTTTCCTTCGCGCCTCT
S14 CCTCACCCATCTTACCCTGA TTGCAGGTCCAGGTCTTTCT
SCD CATCAACCCCCGAGAGAATA GGTGTGGTGGTAGTTGTGGA
SREBF1 AGCTCAAGGACCTGGTGGTG GCTGAAGGAAGCGGATGTAG
1 Primers were designed from specific ovine sequences or based on highly conserved DNA
sequences among related species.
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